Abstract
Primary metabolic disorders and storage diseases are caused by endogenous factors, usually a gene mutation. Since the congenital defect is predominantly or exclusively located in the liver, the resulting diseases also become manifest in this organ.
Chapter PDF
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Andersen, T., Gluud, C.: Liver morphology in morbid obesity: a literature study. Int. J. Obes. 1984; 8: 97–106
Angelico, F., del Ben, M., Conti, R., Francioso, S., Feole, K., Maccioni, D., Antonini, T.M., Alessandri, C.: Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J. Gastroenterol. Hepatol. 2003; 18: 588–594
Ballard, H., Bernstein, M., Farras, J.I.: Fatty liver presenting as obstructive jaundice. Amer. J. Med. 1961; 30: 196–201
Bedogni, G., Miglioli, L., Battistini, N., Masutti, F., Tiribelli, C., Bellentani, S.: Body mass index is a good predictor of an elevated alanine transaminase level in the general population: hints from the Dionysos study. Dig. Liver Dis. 2003; 35: 648–652
Braillon, A., Capron, J.P., Hervé, M.A., Degott, C., Quenum, C.: Liver in obesity. Gut 1985; 26: 133–139
Burt, A.D., Mutton, A., Day, C.P.: Diagnosis and interpretation of steatosis and steatohepatitis. Semin. Diagn. Pathol. 1998; 15: 246–258
Caturelli, E., Squillante, M.M., Andriulli, A., Cedrone, A., Cellerino, C., Pompili, M., Manoja, E.R., Rapaccini, G.L.: Hypoechoic lesions in the “bright liver”: a reliable indicator of fatty change. A prospective study. J. Gastroenterol. Hepatol. 1992; 7: 469–472
Chong, V.F., Fan, Y.F.: Ultrasonographic hepatic pseudolesions: normal parenchyma mimicking mass lesions in fatty liver. Clin. Radiol. 1994; 49: 326–329
Christl, S.U., Müller, J.G.: Fatty liver in adult celiac disease. Dtsch. Med. Wschr. 1999; 124: 691–694
Clark, J.M., Diehl, A.M.: Nonalcoholic fatty liver disease. An under-recognized cause of cryptogenic cirrhosis. J. Amer. Med. Ass. 2003; 289: 3000–3004
Dixon, J.B., Bhathal, P.S., Hughes, N.R., O’Brien, P.E.: Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004; 39: 1647–1654
Giorgio, A., Francica, G., Aloisio, T., Tarantino, L., Pierri, P., Pellicano, M., Buscarini, L., Livraghi, T.: Multifocal fatty infiltration of the liver mimicking metastatic disease. Gastroenterol. Internat. 1991; 4: 169–172
Goland, S., Shimoni, S., Zornitzki, T., Knobler, H., Azoulai, O., Lutaty, G., Melzer, E., Orr, A., Caspi, A., Malnick, S.: Candiac abnormalities as a new manifestation of nonalcoholic fatty liver disease. Echocardiographic and tissue Doppler imaging assessment. J. Clin. Gastroenterol. 2006; 40: 949–955
Hartroft, W.S., Sugioka, E., Porta, E.A.: Nutritional types of fatty livers in experimental animals and man. 5. Meeting-Internat. Assoc. Study of the Liver. Karlsbad 1968
Hautekeete, M.L., Degott, C., Benhamou, J.-P.: Microvesicular steatosis of the liver. Acta Clin. Belg. 1990; 45: 311–326
Jepsen, P., Vilstrup, H., Mellemkjall, L., Thulstrup, A.M., Olsen, J.H., Baron, J.A., Sorensen, H.T.: Prognosis of patients with a diagnosis of fatty liver. A registry-based cohort study. Hepato-Gastroenterol. 2003; 50: 2101–2104
Kemper, J., Jung, G., Poll, L.W., Jonkmanns, C., Luthen, R., Moedder, U.: CT and MRI findings of multifocal hepatic steatosis mimicking malignancy (case report). Abdom. Imag. 2002; 27: 708–710
Kral, J.G., Schaffner, F., Pierson, R.N.jr., Wang, J.: Body fat topography as an independent predictor of fatty liver. Metabolism 1993; 42: 548–551
Kuntz, E.: Fatty liver — a morphological and clinical review. Med. Welt 1999; 50: 406–413
Levenson, H., Greensite, F., Hoefs, J., Friloux, L., Applegate, G., Silva, E., Kanel, G., Buxton, R.: Fatty infiltration of the liver: quantification with phase-contrast MR imaging at 1.5 T vs biopsy. Amer. J. Roentgenol. 1991; 156: 307–312
Marchesini, G., Brizi, M., Morselli-Labate, A.M., Bianchi, G., Bugianesi, E., McCullogh, A.J., Forlani, G., Melchionda, N.: Association of nonalcoholic fatty liver disease with insulin resistance. Amer. J. Med. 1999; 107: 450–455
Mathiesen, U.L., Franzen, L.E., Aselius, H., Resjo, M., Jacobsson, L., Foberg, U., Fryden, A., Bodemar, G.: Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig. Dis. Sci. 2002; 34: 516–522
Mofrad, P., Contos, M.J., Haque, M., Sargeant, C., Fisher, R.A., Luketic, V.A., Sterling, R.K., Shiffman, M.L., Stravitz, R.T., Sanyal, A.J.: Clinical and histologic spectrum of non-alcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286–1292
Naschitz, J.E., Yeshurun, D., Zuckerman, E., Arad, E., Boss, J.H.: Massive hepatic steatosis complicating adult celiac disease: report of a case and review of the literature. Amer. J. Gastroenterol. 1987; 82: 1186–1189
Newman, J.S., Oates, E., Arora, S., Kaplan, M.: Focal spared area in fatty liver simulating a mass. Scintigraphic evaluation. Dig. Dis. Sci. 1991; 36: 1019–1022
Nomura, F., Ohnishi, K., Ochiai, T., Okuda, K.: Obesity-related nonalcoholic fatty liver: CT features and follow-up studies after low-calorie diet. Radiology 1987; 162: 845–847
Nussbaum, M.S., Li, S., Bower, R.H., McFadden, D.W., Dayal, R., Fischer, J.E.: Addition of lipid to total parenteral nutrition prevents hepatic steatosis in rats by lowering the portal venous insulin/glucagon ratio. J. Parent. Ent. Nutr. 1992; 16: 106–109
Quigley, E.M.M.M., Marsh, N., Shaffer, J.L., Markin, R.S.: Hepatobiliary complications of total parenteral nutrition. Gastroenterology 1993; 104: 286–301
Roediger, W.E.W.: New views on the pathogenesis of kwashiorkor: methionine and other amino acids. J. Pediatr. Gastroenterol. Nutr. 1995; 21: 130–136
Schulz, F., Hildebrand, E.: Exzessive generalisierte Fettembolie bei akut dystrophischer Fettleber. Med. Klin. 1977; 72: 59–63.
Seifalian, A.M., Piasecki, C., Agarwal, A., Davidson, B.R.: The effect of graded steatosis on flow in the hepatic parenchymal microcirculation. Transplantation 1999; 68: 780–784
Silverman, J.F., Pories, W.J., Caro, J.F.: Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Path. Ann. 1989; 24: 275–302
Tanaka, K., Kean, E.A., Johnson, B.: Jamaican vomiting sickness. Biochemical investigation of two cases. New Engl. J. Med. 1976; 295: 461–467
Teli, M.R., James, O.F.W., Burt, A.D., Bennett, M.K., Day, C.P.: The natural history of non-alcoholic fatty liver: a follow-up study: Hepatology 1995; 22: 1714–1719
Tendler, D., Lin, S., Yancy, W.S., Mavropoulos, J., Sylvestre, P., Rockey, D.C., Westman, E.C.: The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease. A pilot study. Dig. Dis. Sci. 2007; 52: 589–593
Tsushima, Y., Endo, K.: Spleen enlargement in patients with nonalcoholic fatty liver — Correlation between degree of fatty infiltration in liver and size of spleen. Dig. Dis. Sci. 2000; 45: 196–200
Waterlow, J.C.: Kwashiorkor revisited: the pathogenesis of oedema in kwashiorkor and its significance. Trans. R. Soc. Trop. Med. Hyg. 1984; 78: 436–441
Younossi, Z.M., Gramlich, T., Matteoni, C.A., Boparai, N., McCullogh, A.J.: Non-alcoholic fatty liver disease in patients with type 2 diabetes. Clin. Gastroenterol. Hepatol. 2004; 2: 262–265
Zafrani, E.S.: Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virch. Arch. 2003; 444: 3–12
Non-alcoholic steatohepatitis
Abdelmalek, M.F., Angulo, P., Jorgensen, R.A., Sylvestre, P.B., Lindor, K.D.: Betaine, a promising new agent for patients with nonalcoholic steato-hepatitis: results of a pilot study. Amer. J. Gastroenterol. 2001; 96: 2711–2717
Angulo, P., Keach, J.C., Batts, K.P., Lindord, K.D.: Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 1999; 30: 1356–1362
Brunt, E.M., Janney, C.G., DiBisceglie, A.M., Neuschwander-Tetri, B.A., Bacon, B.R.: Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Amer. J. Gastroenterol. 1999; 94: 2467–2474
Caldwell, S.H., Swerdlow, R.H., Khan, E.M., Iezzoni, J.C., Hespenheide, E.E., Parks, J.K., Parker, W.D.: Mitochondrial abnormalities in non-alcoholic steatohepatitis. J. Hepatol. 1999; 31: 430–434
Carson, K., Washington, M.K., Treem, W.R., Clavien, P.A., Hunt, C.M.: Recurrence of non-alcoholic steatohepatitis in a liver transplant recipient. Liver Transpl. Surg. 1997; 3: 174–176
Chen, S.W., Chen, Y.X., Shi, J., Lin Y., Xie, W.F.: The restorative effect of taurine on experimental nonalcoholic steatohepatitis. Dig. Dis. Sci. 2006; 51: 2225–2234
Chitturi, S., Farrell G., Frost, L., Kriketos, A., Lin, R., Liddle, C., Samarasinghe, D., George, J.: Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002; 36: 403–409
Cotrim, H.P., Andrade, Z.A., Parana, R., Portugal, M., Lyra, L.G., Freitas, L.A.R.: Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. Liver 1999; 19: 299–304
Denk, H., Stumptner, C., Fuchsbichler, A., Zatloukal, K.: Alcoholic and nonalcoholic steatohepatitis. Histopathologic and pathogenetic considerations. Pathologe 2001; 22: 388–398
Eriksson, S., Eriksson, K.-F., Bondesson, L.: Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med. Scand. 1986; 220: 83–88
George, D.K., Goldwurm, S., MacDonald, G.A., Cowley, L.L., Walker, N.I., Ward P.J., Jazwinska, E.C., Powell, L.W.: Increased hepatic iron concentration in, non-alcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311–318
Harrison, S.A., Torgerson, S., Hayashi, P., Ward, J., Schenker, S.: Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Amer. J. Gastroenterol. 2003; 98: 2485–2490
Itoh, S., Yougel, T., Kawagoe, K. Comparison between non-alcoholic steatohepatitis and alcoholic hepatitis. Amer. J. Gastroenterol. 1987; 82: 650–654
James, O., Day, C.: Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999; 353: 1634–1636
Koruk, M., Savas, C., Yilmaz, O., Taysi, S., Karokok, M., Gündogdu, C., Yilmaz, A.: Serum lipids, lipoproteins and aplipoprotein levels in patients with nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2003; 37: 177–182
Laurin, J., Lindor, K.D., Cripin, J.S., Gossard, A., Gores, G.J., Ludwig, J.: Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464–1467
Liangpunsakul, S., Chalasani, N.: Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? J. Clin. Gastroenterol. 2003; 37: 340–343
Ludwig, J., Viggiano, T.R. McGill, D.B., Oh, B.J.: Nonalcoholic steatohepatitis: Majo Clinic experiences with a hitherto unnamed disease. Majo Clin. Proc. 1980; 55: 434–438
Molleston, J.P., White, F., Teckman, J., Fitzgerald, J.F.: O bese children with steatohepatitis can develop cirrhosis in childhood. Amer. J. Gastroenterol. 2002; 97: 2460–2462
Molloy, R.M., Komorowski, R., Varma, R.R.: Recurrent non-alcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transpl. Surg 1997; 3: 177–178
Neuschwander-Tetri, B.A., Brunt, E.M., Wehmeier, K.R., Oliver, D., Bacon, B.R.: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008–1017
Ohbayashi, H.: Twelve-month chronic administration of polyenephos-phatidylcholine (EPL) for improving hepatic function of fatty liver patients. Progr. Med. 2004; 24: 1751–1756
Perez-Carreras, M., del Hoyo, P., Martin, M.A., Rubio, J.C., Martin, A., Castellano, G., Colina, F., Arenas, J., Solis-Herruzo, J.A. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003; 38: 999–1007
Powell, E.E., Cooksley, W.G., Hanson, R., Searle, J., Halliday, J.W., Powell, L.W.: The natural history of non-alcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74–80
Roberts, E.A.: Nonalcoholic steatohepatitis in children. Curr. Gastroenterol. Rep. 2003; 5: 253–259
Saibara, T.: “Insuffient” leptin production for the fat mass: a risk factor for nonalcoholic steatohepatitis in obese patients? J. Gastroenterol. 2003; 38: 522–523
Savas, M.C., Koruk, M., Pirim, I., Yilmaz, O., Karakok, M., Taysi, S., Yilmaz, A.: Serum ubiquitin levels in patients with nonalcoholic steatohepatitis. Hepato-Gastroenterol. 2003; 50: 738–741
Shimada, M., Hashimoto, E., Kaneda, H., Noguchi, S., Hayashi, N.: Nonalcoholic steatohepatitis: risk factors for liver fibrosis. Hepatol. Res. 2002; 24: 429–438
Sorbi, D., Boynton, J., Lindor, K.D.: The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differenting non-alcoholic steatohepatitis from alcoholic liver disease. Amer. J. Gastroenterol 1999; 94: 1018–1021
Struben, V.M.D., Espenheide, E.E., Caldwell, S.H.: Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Amer. J. Med. 2000; 108: 9–13
Sumida, Y., Nakashima, T., Yoh, T., Furutani, M., Hirohama, A., Kakisaka, Y. Nakajima, Y., Ishikawa, H., Mitsuyoshi, H., Okanoue, T., Kashima, K., Nakamura, H., Yodoi, J.: Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J. Hepatol. 2003; 38: 32–38
Tajiri, K., Takenawa, H., Yamaoka, K., Yamane, M., Marumo, F., Sato, C.: Nonalcoholic steatohepatitis masquerading as autoimmune hepatitis. J. Clin. Gastroenterol. 1997; 25: 538–540
Thaler, H.: Die Fettleber und ihre pathogenetische Beziehung zur Leberzirrhose. Virch. Arch. Path. Anat. 1962; 335: 180–210
Yang, S.Q., Lin, H.Z., Lane, M.D., Clemens, M., Diehl, A.M.: Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc. Nat. Acad. Sci. 1997; 94: 2557–2562
Zamin, I., Alves-de-Mattos, A., Zettler, C.G.: Nonalcoholic steatohepatitis in nondiabetic obese patients. Can. J. Gastroenterol. 2002; 16: 303–307
Reye’s syndrome
Arrowsmith, J.B., Kennedy, D.L., Kuritsky, J.N., Faich, G.A.: National patterns of aspirin use and Reye’s syndrome reporting United States, 1980 to 1985. Pediatrics 1987; 79: 858–863
Belay, E.D., Bresee, J.S., Holman, R.C., Khan, A.S., Shahriari, A., Schonberger, L.B.: Reye’s syndrome in the United States from 1981 through 1997. New Engl. J. Med. 1999; 340: 1377–1382
Brain, W.R., Hunter, D., Turnbull, H.M.: Acute meningo-encephalomyelitis of childhood: report of six cases. Lancet 1929/I: 221–227
Casteels-van Daele, M. Eggermont, E.: Reye’s syndrome. Brit. Med. J. 1994; 308: 919–920
Gauthier, M., Guay, J., Lacroix, J., Lortie, A.: Reye’s syndrome: a reappraisal of diagnosis in 49 presumptive cases. Amer. J. Dis. Child. 1989; 143: 1181–1185
Glasgow, J.F.: Reye’s syndrome: The case for a causal link with aspirin. Drug Safety 2006; 29: 1111–1121
Hall, S.M., Plaster, P.A., Glasgow, J.F., Hancock, P.: Preadmission antipyretics in Reye’s, syndrome. Arch. Dis. Child. 1988; 63: 857–866
Hardie, R.M., Newton, L.H., Bruce, J.C., Glasgow, J.F.T., Mowat, A.P., Stephenson, J.B.P., Hall, S.M.: The changing clinical pattern of Reye’s syndrome 1982–1990. Arch. Dis. Childh 1996; 74: 400–405
Heubi, J.E., Partin, J.C., Partin J.S., Schubert, W.K.: Reye’s syndrome: current concepts. Hepatology 1987; 7: 155–164
Hilty M.D., McClung, H.-J., Haynes, R.E., Romshe, C.A., Sherard, E.S.: Reye’s syndrome in siblings. J. Pediatr. 1979; 94: 576–579
Meythaler, J.M., Varma, R.R.: Reye’s syndrome in adults. Diagnostic considerations. Arch. Intern. Med. 1987; 147: 61–64
Pinsky, P.F., Hurwitz, E.S., Schonberger, L.B., Gunn, W.J.: Reye’s syndrome and aspirin. Evidence for a dose-response effect. J. Amer. Med. Ass. 1988; 260: 657–661
Reye, R.D.K., Morgan, G., Baral, J. Encephalopathy and fatty degeneration of the viscera. A disease entity in childhood. Lancet 1963/II: 749–751
Stillmann, A., Gitter, H., Shillington, D., Sobonya, R., Payne, C.M., Ettinger, D., Lee, M.S.: Reye’s syndrome in the adult: case report and review of the literature. Amer. J. Gastroenterol. 1983; 78: 365–368
Acute fatty liver of pregnancy
Barton, J.R., Sibai, B.M., Mabie, W.C., Shanklin, D.R.: Recurrent acute fatty liver of pregnancy. Amer. J. Obstet. Gynec. 1990; 163: 534–538
Fesenmeier, M.F., Coppage, K.H., Lambers, D.S., Barton, J.R., Sibai, B.M.: Acute fatty liver of pregnancy in 3 tertiary care centers. Amer. J. Obstetr. Gynecol. 2005; 192: 1416–1419
Ko, H.H., Yoshida, E.: Acute fatty liver of pregnancy. Can. J. Gastroenterol. 2006; 20: 25–30
Kunelis, C.T., Peters, J.E., Edmondson, H.A.: Fatty liver of pregnancy and its relation to tetracycline therapy. Amer. J. Med. 1985; 38: 359–377
Mabie, W.C.: Acute fatty liver of pregnancy. Gastroenterol. Clin. N. Amer. 1992; 21: 951–960
McKee, C.M., Weir, P.E., Foster, J.H., Murnaghan, G.A., Callender, M.E.: Acute fatty liver of pregnancy and diagnosis by computed tomography. Brit. Med. J. 1986; 292: 291–292
Minuk, G.Y., Lui, R.C., Kelly, J.K.: Rupture of the liver associated with acute fatty liver of pregnancy. Amer. J. Gastroenterol. 1987; 82: 457–460
Moise, K.J., Shah, D.M.: Acute fatty liver of pregnancy: etiology of fetal distress and fetal wastage. Obstetr. Gynec. 1987; 69: 482–485
Ockner, S.A., Brunt, E.M., Cohn, S.M., Krul, E.S., Hanto, D.W., Peters, M.G.: Fulminant hepatitic failure caused by acute fatty liver of pregnancy treated by orthotopic liver transplantation. Hepatology 1990; 11: 59–64
Reyes, H., Sandoval, L., Wainstein, A., Ribalta, J., Donoso, S., Smok, G., Rosenberg, H., Meneses, M.: Acute fatty liver of pregnancy: a clinical study of 12 episodes in 11 patients. Gut 1994; 35: 101–106
Riely, C.A., Latham, P.S., Romero, R., Duffy, T.P.: Acute fatty liver of pregnancy. A reassessment based on observations in nine patients. Ann. Intern. Med. 1987; 106: 703–706
Sheehan, H.L.: The pathophysiology of acute yellow atrophy and delayed chloroform poisoning. J. Obstetr. Gynaec. Brit. Emp. 1940; 47: 49–62
Sherlock, S.: Acute fatty liver of pregnancy and the microvesicular fat diseases. Gut 1983; 24: 265–269
Stander, H.J., Cadden, J.F.: Acute yellow atrophy of liver in pregnancy. Amer. J. Obstetr. Gynec. 1934; 28: 61–69
Tan, A.C.I.T.L., van Krieken, J.H.J.M., Peters, W.H.M., Steegers, E.A.P.: Acute fatty liver in pregnancy (case report). Neth. J. Med. 2002; 60: 370–373
Treem, W.R. Rinaldo, P., Hale, D.E., Stanley, C.A., Millington, D.S., Hyams, J.S., Jackson, S., Turnbull, D.M.: Acute fatty liver of pregnancy and long-chain 3-hydroxyacyl coenzyme A dehydrogenase deficiency. Hepatology 1994; 19: 339–345
Van Le, L., Podrasky, A.: Computed tomographic and ultrasonographic findings in women with acute fatty liver of pregnancy. J. Reprod. Med. 1990; 35: 815–817
Yang, W.W., Shen, Z.J., Peng, G.D., Chen, Y.G., Jiang, S.F., Kang, S.Y., Wu, J.C.: Acute fatty liver of pregnancy: diagnosis and management of 8 cases. Chin. Med. J. 2000; 113: 540–543
Zürcher, K.: Unkomplizierte Zweitschwangerschaft nach akuter Schwangerschaftsfettleber. Schweiz. Med. Wschr. 1995; 125: 1003–1005
Mauriac syndrome
Mandell, F., Berenberg, W.: The Mauriac syndrome. Amer. J. Dis. Child. 1974; 127: 900–902
α1 deficiency
Bell, H., Schrumpf, E., Fagerhol, M.K.: Heterozygous MZ alpha-1-antitrypsin deficiency in adults with chronic liver disease. Scand. J. Gastroenterol. 1990; 25: 778–792
Carrell, R.W., Lomas, D.A.: Mechanisms of disease-Alpha-1-antitrypsin deficiency. A model for conformational diseases (review). New Engl. J. Med. 2002; 346: 45–53
Crystal, R.G.: α1 deficiency, emphysema and liver disease, Genetic basis and strategies for therapy. J. Clin. Invest. 1990; 85: 1343–1352
Deutsch, J., Becker, H., Auböck, L.: Histopathological features of liver disease in alpha-1 antitrypsin deficiency. Acta Paediatr. 1994; 393(Suppl.): 8–12
Eriksson, S., Elzouki, A.-N.: α1 deficiency. Baill. J. Gastroenterol. 1998; 12: 257–273
Filipponi, F., Soubrane, O., Labrousse, F., Devictor, D., Bernard, O., Valayer, J., Houssin, D.: Liver transplantation for end-stage liver disease associated with α1 deficiency in children: pretransplant natural history, timing and results of transplantation. J. Hepatol. 1994; 20: 72–78
Fischer, H.-P., Ortiz-Pallardo, M.E., Ko, Y., Esch, C., Zhou, H.: Chronic liver disease in heterozygous α1 deficiency PiZ. J. Hepatol. 2000; 33: 883–892
Francavilla, R., Castellaneta, S.P., Hadzic, N., Chambers, S.M., Portmann, B., Tung, J., Cheeseman, P., Heaton, N.D., Mieli-Vergani, G.: Prognosis of alpha-1-antitrypsin deficiency-related liver disease in the era of pediatric liver transplantation. J. Hepatol. 2000; 32: 986–992
Löhr, H.F., Schlaak, J.F., Dienes, H.P., Lorenz, J., Meyer zum Büschenfelde, K.-H., Gerken, G.: Liver cirrhosis associated with heterozygous alpha-1-antitrypsin deficiency type PiMS and autoimmune features. Digestion 1995; 56: 41–45
Lomas, D.A., Mahadeva, R.: Alpha(1)-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy (review). J. Clin. Invest. 2002; 110: 1585–1590
Mowat, A.P.: Alpha-1-antitrypsin deficiency (PiZZ): features of liver involvement in childhood. Acta Paediatr. 1994; 393(Suppl.): 13–17
Pittschieler, K., Massi, G.: Liver involvement in infants with PiSZ phenotype of α1 deficiency. J. Pediatr. Gastro. Nutrit. 1992; 15: 315–318
Prachalias, A.A., Kalife, M., Francavilla, R., Muiesan, P., Dhawan, A., Baker, A., Hadzic, D., Mieli-Vergani, G., Rela, M., Heaton, N.D.: Liver transplantation for alpha-1-antitrypsin deficiency in children. Transplant. Internat. 2000; 13: 207–210
Propst, T., Propst, A., Dietze, O., Judmaier, G., Braunsteiner, H., Vogel, W.: Prevalence of hepatocellular carcinoma in alpha-1-antitrypsin deficiency. J. Hepatol. 1994; 21: 1006–1011
Rudnick, D.A., Shikapwashya, O., Blomenkamp, K., Teckman, J.H.: Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency. Hepatology 2006; 44: 976–982
Sifers, R.N., Finegold, M.J., Woo, S.L.C.: Molecular biology and genetic of α1 deficiency. Semin. Liver Dis 1992; 12: 301–310
Steiner, S.J., Gupta, S.K., Croffie, J.M., Fitzgerald, J.F.: Serum levels of alpha(1)-antitrypsin predict phenotypic expression of the alpha(1)-antitrypsin gene. Dig. Dis. Sci. 2003; 48: 1793–1796
Sveger, T., Eriksson, S.: The liver in adolescents with α1 deficiency. Hepatology 1995; 22: 514–517
Yoon, D., Kueppers, F., Genta, R.M., Klintmalm, G.B., Khaoustov, V.I., Yoffe, B.: Role of alpha-1-antichymotrypsin deficiency in promoting cirrhosis in two siblings with heterozygous alpha-1-antitrypsin deficiency phenotype SZ (case report). Gut 2002; 50: 730–732
Zhou, H., Ortiz-Pallardo, M.E., Ko, Y., Fischer, H.-P.: Is heterozygous alpha-1-antitrypsin deficiency type PiZ a risk factor for primary liver carcinoma? Cancer 2000; 88: 2668–2676
Amyloidosis
Arkenau, H.T., Widjaja, A.: An unusual case of cholestasis and makrohematuria in a 52-year-old patient. Med. Klin. 2002; 97: 480–483
Caballeria, J., Bruguera, M., Sole, M., Campistol, J.M., Rodes, J.: Hepatic familial amyloidosis caused by a new mutation in the AL gene: clinical and pathological features. Amer. J. Gastroenterol. 2001; 96: 1872–1876
Diel, R., Krüger, C.: Primäre Amyloidose als seltene Ursache einer akuten Leberinsuffizienz. Dtsch. Med. Wschr. 1988; 113: 1433–1436
Frank, H., Krammer, M., Fierlbeck, W., Rieß, R., Geiger, H.: Unusual hepatorenal symptoms in amyloidosis. Med. Klin. 1999; 94: 274–278
Gertz, M.A., Kyle, R.A.: Hepatic amyloidosis: clinical appraisal in 77 patients. Hepatology 1997; 25: 118–121
Harrison, R.F., Hawkins, P.N., Roche, W.R., MacMahon, R.F.T., Hubscher, S.G., “Fragile” liver and massive hepatic haemorrhage, due to hereditary amyloidosis. Gut 1996; 38: 151–152
Hawkins, P.N., Pepys, M.B.: Imaging amyloidosis with radiolabelled SAP. Eur. J. Nucl. Med. 1995; 22: 595–599
Hoffmann, M.S., Stein, B.E., Davidian, M.M., Rosenthal, W.S.: Hepatic amyloidosis presenting as severe intrahepatic cholestasis: a case report and review of the literature. Amer. J. Gastroenterol. 1988; 83: 783–785
Holmgren, G., Ericzon, B.G., Groth, C.G., Stein, L., Suhr, O., Andersen, O., Wallin, B.G., Seymour, A., Richardson, S., Hawkins, P.N., Petys, M.B.: Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341: 1113–1116
Iwai, M., Ishii, Y., Mori, T., Harada, Y., Kitagawa, Y., Kashiwadani, M., Ou, O., Okanoue, T., Kashima, K.: Cholestatic jaundice in two patients with primary amyloidosis. Ultrastructural findings of the liver. J. Clin. Gastroenterol. 1999; 28: 162–166
Jorquera Plaza, F., Fernandez Gundin, M.J., Espinel Diez, J., Munoz Nunez, F., Herrera Abian, A., Garcia Lagarto, E., Olcoz Goni, J.L.: Iciericia colestasica como forma de presentacion de una amiloidosis sistemica. Rev. Esp. Enferm. Dig. 1997; 89: 859–861
Kumar, K.S., Lefkowitch, J., Russo, M.W., Hesdorffer, C., Kinkhabwala, M., Kapur, S., Emond, J.C., Brown, R.S.: Successful sequential liver and stem cell transplantation for hepatic failure due to primary AL amyloidosis. Gastroenterology 2002; 122: 2026–2031
Llovat, L.B., Persey, M.R., Madhoo, S., Hawkins, P.N.: The liver in systemic amyloidosis: insights from 1231 serum amyloid P component scintigraphy in 484 patients. Gut 1998; 42: 727–734
Mainenti, P.P., D’Agostino, L., Soscia, E., Romano, M., Salvatore, M.: Hepatic and splenic amyloidosis: dual-phase spiral CT findings. Abdom. Imag. 2003; 28: 688–690
Mohr, A., Miehlke, S., Klauck, S., Röcken, C., Malfertheiner, P.: Hepatomegaly and cholestasis as primary clinical manifestations of an AL-kappa amyloidosis. Europ. J. Gastroenterol. Hepatol. 1999; 11: 921–925
Monzawa, S., Tsukamoto, T., Omata, K., Hosoda, K., Araki, T., Sugimura, K.: A case with primary amyloidosis of the liver and spleen: radiologic findings. Eur. J. Radiol. 2002; 41: 237–241
Nowak, G., Westermark, P., Wernerson, A., Herlenius, G., Sletten, K., Ericzon, B.G.: Liver transplantation as rescue treatment in a patient with primary AL kappa amyloidosis. Transpl. Internat. 2000; 13: 92–97
Peters, R.A., Koukoulis, G., Glimson, A., Portamm, B., Westaby, D., William, R.: Primary amyloidosis and severe intrahepatic cholestatic jaundice. Gut 1994; 35: 1322–1325
Sandberg-Gertzen, H., Ericzon, B.G., Blomberg, B.: Primary amyloidosis with spontaneous splenic rupture, cholestasis, and liver failure treated with emergency liver transplantation. Amer. J. Gastroenterol. 1998; 93: 2254–2256
Straub, R.F., Boyer, T.D.: The liver-spleen scan in systemic amyloidosis: a clue to the diagnosis. J. Clin. Gastroenterol. 1993; 16: 340–343
Ubina Aznar, E., Fernandez Moreno, N., Rivera Irigoin, R., Moreno Mejias, P., Fernandez Perez, F., Vera Rivero, F., Navarro Jarabo, J.M., Garcia Fernandez, G., de Sola Earle, C., Perez Aisa, A., Sanchez Santos, A.: Massive hepatic amyloidosis with fatal hepatic failure (case report). Rev. Espan. Enferm. Dig. 2006; 98: 551–552
α1 deficiency
Callea, F., Brisigotti, M., Fabbretti, G., Bonino, F., Desmet, V.J.: Hepatic endoplasmatic reticulum storage diseases Liver 1992; 12: 357–362
Eriksson, S., Lindmark, B., Lilja, H.: Familial α1 deficiency. Acta Med. Scand. 1986; 220: 447–453
Lindmark, B., Eriksson, S.: Partial deficiency of α1-antichymotrypsin is associated with chronic cryptogenetic liver disease. Scand. J. Gastroenterol. 1991; 26: 508–512
Hereditary tyrosinaemia
Dehner, L.P., Snover, D.C., Sharp, H.L., Ascher, N., Nakhleh, R., Day, D.L.: Hereditary tyrosinemia type I (chronic form): Pathologic findings in the liver. Hum. Path. 1989; 20: 149–158
Demers, S.I., Russo, P., Lettre, F., Tanguay, R.M.: Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia. Hum. Pathol. 2003; 34: 1313–1320
Freese, D.K., Tuchman, M., Schwarzenberg, S.J., Sharp, H.L., Rank, J.M., Bloomer, J.R., Ascher, N.L., Payne, W.D.: Early liver transplan-tation is indicated for tyrosinemia type I. J. Paediatr. Gastroenterol. Nutr. 1991; 13: 10–15
Grompe, M.: The pathophysiology and treatment of hereditary tyrosinemia type 1. Semin. Liver Dis. 2001; 21: 563–571
Kvittingen, E.A.: Hereditary tyrosinemia type I — an overview. Scand. J. Clin. Lab. Invest. 1986; 46: 27–34
Lindstedt, S., Holme, E., Lock, E.A., Hjalmarson, O., Strandvik, B.: Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992; 340: 813–817
Macvicar, D., Dicks-Mireaux, C., Leonard, J.V., Wight, D.G.D.: Hepatic imaging with computed tomography of chronic tyrosinaemia type 1. Brit. J. Radiol. 1990; 63: 605–608
Van Spronsen, F.J., Thomasse, Y., Smith, G.P.A., Leonard, J.V., Clayton, P.T., Fidler, V., Berger, R., Heymans, H.S.A.: Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 1994; 20: 1187–1191
Disturbances of the urea cycle
Berry, G.T., Steiner, R.D.: Long-term management of patients with urea cycle disorders. J. Pediatr. 2001; 138: 56–60
Maestri, N.E., Brusilow, S.w., Clissold, D.B., Bassett, S.S.: Long-term treatment of girls with ornithine transcarbamylase deficiency. New Engl. J. Med. 1996; 335: 855–859
Mönch, E., Hoffmann, G.F., Przyrembel, H., Colombo, J.-P., Wermuth, B., Leonard, J.V.: Diagnosis and treatment of ornithine transcarbamylase (OTC)-deficiency. Mschr. Kinderheilkd. 1998; 146: 652–658
Takagi, H., Hagiwara, S., Hashizume, H., Kanda, D., Sato, K., Sohara, N., Kakizaki, S., Takahashi, H., Mori, M., Kaneko, H. Ohwada, S., Ushikai, M., Kobayashi, K., Saheki, T.: Adult onset type II cirtrullinemia as a cause of non-alcoholic steatohepatatis (case report). J. Hepatol. 2006; 44: 236–239
Tuchman, M., Matsuda, I., Munnich, A., Malcolm, S., Strautnieks, S., Briede, T.: Proportions of spontaneous mutations in males and females with ornithine transcarbamylase deficiency. Amer. J. Med. Genet. 1995; 55: 67–70
Glycogen storage diseases
Bodamer, O.A., Feillet, F., Lane, R.E., Lee, P.J., Dixon, M.A., Halliday, D., Leonard, J.V.: Utilization of cornstarch in glycogen storage disease type Ia. Eur. J. Gastroenterol. Hepatol. 2002; 14: 1251–1256
Burchell, A.: Glycogen storage diseases and the liver. Baill. Clin. Gastroenterol. 1998; 12: 337–353
Conti, J.A., Kemeny, N.: Type Ia glycogenosis associated with hepatocellular carcinoma. Cancer 1992; 69: 1320–1322
Demo, E., Frush, D., Gottfried, M., Koepke, J., Boney, A., Bali, D., Chen, Y.T., Kishnani, P.S.: Glycogen storage disease type III-hepatocellular carcinoma a long-term complication? J. Hepatol. 2007; 46: 492–498
De Moor, R.A., Schweizer, J.J., van Hoek, B., Wasser, M., Vink, R., Maaswinkel-Mooy, P.D.: Hepatocellular carcinoma in glycogen storage disease type IV. Arch. Dis. Childh. 2000; 82: 479–480
Fernandes, J.: Glycogen storage disease: recommendations for treatment. Europ. J. Pediat. 1988; 147: 226–228
Lee, P., Mather, S., Owens, J., Leonard, J., Dicksmireaux, C.: Hepatic ultrasound findings in the glycogen storage diseases Brit. J. Radiol. 1994; 67: 1062–1066
Lei, K.-J., Pan, C.-J., Liu, J.-L., Shelly, L.L., Yang Chou, J.: Structure-function analysis of human glucose-6-phosphatase, the enzyme deficient in glycogen storage disease type Ia. J. Biol. Chem. 1995; 270: 11882–11886
Limmer, J., Fleig, W.E., Leupold, D., Bittner, R., Ditschuneit, H., Beger, H.G.: Hepatocellular carcinoma in type I glycogen storage disease. Hepatology 1988; 8: 531–537
Marfaing-Koka, A., Wolf, M., Boyer-Neumann, C., Meyer, D., Odievre, T., Labrune, T.: Increased levels of hemostatic proteins are independent of inflammation in glycogen storage disease type Ia. J. Pediatr. Gastroenterol. Nutr. 2003; 37: 586–570
Martin, K., Schlotter, B., Müller-Höcker, J. Loeschke, K., Pongratz, D., Folwaczny, C.: 26-year old female patient with elevated liver enzymes. Z. Gastroenterol. 2002; 40: 885–890
Parker, P., Burr, I., Slonimi, A., Ghishan, F.K., Greene, H.: Regression of hepatic adenomas in type Ia glycogen storage disease with dietary therapy. Gastroenterology 1981; 81: 534–536
Rosh, J.R., Collins, J., Groisman, G.M., Schwersenz, A.H., Schwartz, M., Miller, C.M., LeLeiko, N.S.: Management of hepatic adenoma in glycogen storage disease Ia. J. Pediatr. Gastroenterol. Nutrit. 1995; 20: 225–228
Selby, R., Starzl, T.E., Yunis, E., Todo, S., Tzakis, A.G., Brown, B.I., Kendall, R.S.: Liver transplantation for type I and type IV glycogen storage disease. Eur. J. Pediatr. 1993; 152 (Suppl. 1) 71–76
Siciliano, M., de Candia, E., Ballarin, S., Vecchio, F.M., Servidei, S., Annese, R., Landolfi, R., Rossi, L.: Hepatocellular carcinoma complicating liver cirrhosis in type IIIa glycogen storage disease. J. Clin. Gastroenterol. 2000; 31: 80–82
Talente, G.M., Coleman, R.A., Alter, C., Baker, L., Brown, B.I., Cannon, R.A., Chen, Y.-T., Crigler, J.F., Ferreira, P., Haworth, J.C., Herman, G.E., Issenman, R.M., Keating, J.P., Linde, R., Roe, T.F., Senior, B., Wolfsdorf, J.I.: Glycogen storage disease in adults. Ann. Intern. Med. 1994; 120: 218–226
Galactose intolerance
Berry, G.T., Nissim, I., Lin, Z., Mazur, A.T., Gibson, J.B., Segal, S.: Endogenous synthesis of galactose in normal men and patients with hereditary galactosaemia. Lancet 1995; 346: 1073–1074
Kumar, M., Yachha, S.K., Gupta, R.K.: Neonatal cholestasis syndrome due to galactosemia. Ind. J. Gastroenterol. 1996; 15: 26–27
Monk, A.M., Mitchell, A.J.H., Milligan, D.W.A., Holton, J.B.: The diagnosis of classical galactosaemia. Arch. Dis. Childh. 1977; 52: 943–946
Reichhard, J.K.V.: Mutations in galactosemia. Amer. J. Hum. Genet. 1995; 57: 978–979
Schweitzer, S., Shin, Y., Jakobs, C., Brodehl, J.: Long-term outcome in 134 patients with galactosaemia. Eur. J. Pediatr. 1993; 152: 36–43
Fructose intolerance
Ali, M., Rellos, P., Cox, T.M.: Hereditary fructose intolerance. J. Med. Genet. 1998; 35: 353–365
Mock, D.M., Perman, J.A., Thaler, M.M., Morris, R.C.: Chronic fructose intoxication after infancy in children with hereditary fructose intolerance. A cause of growth retardation. New Engl. J. Med. 1983; 309: 764–770
Odievre, M., Gentil, C., Gautier, M., Alagille, D.: Hereditary fructose intolerance in childhood. Diagnosis management and course in 55 patients. Amer. J. Dis. Childh. 1978; 132: 605–608
Stormon, M.O., Cutz, E., Furuya, K., Bedford, M., Yerkes, L., Tolan, D.R., Feigenbaum, A.: A six-month-old infant with liver steatosis. J. Pediatr. 2004; 144: 258–263
Tolan, D.R.: Molecular basis of hereditary fructose intolerance: mutations and polymorphisms in the human aldolase B gen. Hum. Mut. 1995; 6: 210–218
Wolman’s disease
Fitoussi, G., Negre-Salvayre, A., Pieraggi, M.-T., Salvayre, R.: New pathogenetic hypothesis for Wolman’s disease: possible role of oxidized low-density lipoproteins in adrenal necrosis and calcification. Biochem. J. 1994; 301: 267–273
Lin, H.J., Jie, L.K., Ho, F.C.S.: Accumulation of glyceryl ether lipids in Wolman’s disease. J. Lipid. Res. 1976; 17: 53–56
Wolf, H., Nolte, K., Nolte, R.: Wolman-Syndrom. Mschr. Kinderheilk. 1973; 121: 697–698
Cholesterol ester storage disease
Beaudet, A.L., Ferry, G.D., Nichols, B.F.jr., Rosenberg, H.S.: Cholesterol ester storage disease: clinical, biochemical, and pathological studies. J. Pediatr. 1977; 90: 910–914
Kale, A.S., Ferry, G.D., Hawkins, E.P.: End-stage renal disease in a patient with cholesteryl ester storage disease following successful liver transplantation and cyclosporine immunosuppression. J. Pediatr. Gastroenterol. Nutrit. 1995; 20: 95–97
Kelly, D.R., Hoeg, J.M., Demosky S.J.jr., Brewer, H.B.jr.: Characterization of plasma lipids and lipoproteins in cholesteryl ester storage disease. Biochem. Med. 1985; 33: 29–97
Kuntz, H.D., May, B., Schejbal, V., Assmann, G.: Cholesterinester-Speicherkrankheit der Leber. Leber Magen Darm 1981; 11: 258–263
Limbach, A., Steppberger, K., Naumann, A., Sandig, K., Lohse, P., Keller, E.: Cholesteryl ester storage disease as cause of hepatomegaly in childhood. Mschr. Kinderheilk. 2003; 151: 953–956
Cerebrotendinous xanthomatosis
Berginer, V.M., Salen, G., Shefer, S.: Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. New Engl. J. Med. 1984; 311: 1649–1652
Berginer, V.M., Shany, S., Alkalay, D., Berginer, J., Dekel, S., Salen, G., Tint, G.S., Gazit, D.: Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosis. Metabolism 1993; 42: 69–74
Cali, J.J., Hsieh, C.L., Franke, U., Russel, D.W.: Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J. Biol. Chem. 1991; 266: 7779–7783
Leitersdorf, E., Meiner, V.: Cerebrotendinous xanthomatosis. Curr. Opin. Lipidol. 1994; 5: 138–142
Nakamura, T., Matsuzawa, Y., Takemura, K., Kubo, M., Miki, H., Tarui, S.: Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis. Metabolism 1991; 40: 741–746
Salen, G., Berginer, V.M., Shore, V., Horak, I., Horak, E., Tint, G.S., Shefer, S.: Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. New Engl. J. Med. 1987; 316: 1233–1238
Abeta-hypobetalipoproteinaemia
Black, D.D., Hay, R.V., Rohwer-Nutter, P.L., Ellinas, H., Stephens, J.K., Sherman, H., Teng, B.-B., Whitington, P.F., Davidson, N.O.: Intestinal and hepatic apolipoprotein B gene expression in abetalipoproteinemia. Gastroenterology 1991; 101: 520–528
Castellano, G., Garfia, C., Gomez-Coronado, D., Arenas, J., Manzanares, J., Colina, F., Solis-Herruzo, J.A.: Diffuse fatty liver in familial hererozygous hypobetalipoproteinemia. J. Clin. Gastroenterol. 1997; 25: 379–382
Gregg, R.E., Wetterau, J.R.: The molecular basis of abetalipoproteinemia. Curr. Opin. Lipidol. 1994; 5: 81–86
Hagve, T.-A., Myrseth, L.-E., Schrumpf, E., Blomhoff, J.-P. Christophersen, B., Elgjo, K., Gjone, E., Prydz, H.: Liver steatosis in hypobetalipoproteinemia. A case report. J. Hepatol. 1991; 13: 104–111
Linton, M.F., Farese, R.V., Young, S.G.jr.: Familial hypobetalipoproteinemia. J. Lipid. Res. 1993; 34: 521–541
Rader, D.J., Brewer, H.B.: Abetalipoproteinemia: New insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. J. Amer. Med. Ass. 1993; 270: 865–869
Wetterau, J.R., Aggerbeck, L.P., Bouma, M.E., Eisenberg, C, Munck, A., Hermier, M., Gay, G., Rader, D.J., Gregg, R.E.: Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992; 258: 999–1001
Hypoalphalipoproteinaemia
Brooks-Wilson, A., Marcil, M., Clee, S.M. et al.: Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature Genet. 1999; 22: 336–345
Dechelotte, P., Kantelip, B., de Laguillamie, B.V.: Tangier disease. A histological and ultrastructural study. Path. Res. Pract. 1985; 180: 424–430
Velicia Llames, M.R., Gonzalez Hernandez, J.M., Sanz Santa Cruz, C., Fernandez Orcajo, P., Martinez Barrero, F.: Elevacion de gammaglutamiltranspeptidasa en pacientes con hipoalfalipoproteinemia y dislipemias tipo IIa compensadas. Gastroenterol. Hepatol. 1995; 18: 319–322
Gaucher’s disease
Aderka, D., Garfinkel, D., Rothem, A., Pinkhas, J.: Fatal bleeding from esophageal varices in a patient with Gaucher’s disease. Amer. J. Gastroenterol. 1982; 77: 838–839
Barton, N.W., Brady, R.O., Dambrosia, J.M., Di Bisceglie, A.M., Doppelt, S.H., Hill, S.C., Mankin, H.J., Murray, G.J., Parker, R.I., Argoff, C.E., Grewal, P.P., Yu, K.-T.: Replacement therapy for inherited enzyme deficiency: macrophage targeted glucocerebrosidase for Gaucher’s disease. New Engl. J. Med. 1991; 324: 1464
Beck, M., Valadares, E.R., Lotz, J.: Gaucher’s disease. Therapy by intravenous infusions of modified glucocerebrosidase. Clin. Invest. 1993; 71: 78
Beutler, E.: Gaucher’s disease: new molecular approaches to diagnosis and treatment. Science 1992; 256: 794–799
Cox, T., Lachmann, R., Hollak, C., Aerts, J., van Weely, S., Hrebicek, M., Platt, F., Butters, T., Dwek, R., Moyses, C., Gow, I., Elstein, D., Zimran, A.: Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000; 355: 1481–1485
Fallet, S., Grace, M.E., Sibille, A., Mendelson, D.S., Shapiro, R.S., Hermann, G.; Grabowski, G.A.: Enzyme augmentation in moderate to life-threatening Gaucher’s disease. Pediat. Res. 1992; 31: 496–502
Figueroa, M.L., Rosenbloom, B.E., Kay, A.C., Garver, P., Thurston, D.W., Koziol, J.A., Gelbart, T., Beutler, E.: A less costly regimen of alglucerase to treat Gaucher’s disease. New Engl. J. Med. 1992; 327: 1632–1636
Harzer, K.: Enzymic diagnosis in 27 cases with Gaucher’s disease. Clin. Chim. Acta 1980; 106: 9–15
James, S.P., Stromeyer, F.W., Chang, C., Barranger, J.A.: Liver abnormalities in patients with Gaucher’s disease. Gastroenterology 1981; 80: 126–133
Kohn, D.B., Nolta, J.A., Weinthal, J., Bahner, I., Yu, X.J., Lilley, J., Crooks, G.M.: Toward gene therapy for Gaucher’s disease. Human Gene Ther. 1991; 2: 101–105
Mistry, P.K.: Genotype/phenotype correlations in Gaucher’s disease. Lancet 1995; 346: 982–983
Niederau, C., Holderer, A., Heintges, T., Strohmeyer, G.: Glucocerebrosidase for treatment of Gaucher’s disease: first German long-term results. J. Hepatol. 1994; 21: 610–617
Peters, S.P., Lee, R.E., Glew, R.H.: Gaucher’s disease, a review. Medicine 1977; 56: 425–442
Ringden, O., Groth, C.-G., Erikson, A., Bäckman, L., Granqvist, S., Mansson, J.-E., Svennerholm, L.: Long-term follow-up of the first succesful bone marrow transplantation in Gaucher’s disease. Transplantation 1988; 46: 66–70
Stone, R., Benson, J., Tronic, B., Brennan, T.: Hepatic calcifications in a patient with Gaucher’s disease. Amer. J. Gastroenterol. 1982; 77: 95–98
Tjhen, K.Y., Zillhardt, H.W.: M. Gaucher Typ 1. Verlauf von 4 Geschwistererkrankungen vor und nach Splenektomie. Pädiat. Prax. 1977; 18: 247–260
Zimran, A., Sorge, J., Gross, E., Kubitz, M., West, C., Beutler, E.: Prediction of severity of Gaucher’s disease by identification of mutations at DNA level. Lancet 1989/II: 349–352
Niemann-Pick disease
Birch, N.C., Radio, S., Horslen, S.: Metastatic hepatocellular carcinoma in a patient with Niemann-Pick disease, type C. J. Pediatr. Gastroenterol. Nutr. 2003; 37: 624–626
Kulinski, A., Vance, J.E.: Lipid homeostasis and lipoprotein secretion in Niemann-Pick C1-deficient hepatocytes. J. Biol. Chem. 2007; 282: 1627–1637
Putterman, C., Zelingher, J., Shouval, D.: Liver failure and the sea-blue histiocyte adult Niemann-Pick disease. Case report and review of the literature. J. Clin. Gastroenterol. 1992; 15: 146–149
Smanik, E.J., Tavill, A.S., Jacobs, G.H., Schafer, I.A., Farquhar, L., Weber, F.L., Mayes, J.T., Schulack, J.A., Petrelli, M., Zirzow, G.C., Oliver, K.L., Miller, S.P.F., Brady, R.O.: Orthotopic liver transplantation in two adults with Niemann-Pick and Gaucher’s disease: implications for the treatment of inherited metabolic disease. Hepatology 1993; 17: 42–49
Tassoni, J.P., Fawaz, K.A., Johnston, D.E.: Cirrhosis and portal hypertension in a patient with adult Niemann-Pick disease. Gastroenterology 1991; 100: 567–569
Vellodi, A., Hobbs, J.R., O’Donnell, N.M., Coulter, B.S., Hugh-Jones, K.: Treatment of Niemann-Pick disease type B by allogeneic bone marrow transplantation. Brit. Med. J. 1987; 295: 1375–1376
Yerusalem, B., Sokol, R.J., Narkewicz, M.R., Smith, D., Ashmead, J.W., Wenger, D.A.: Niemann-Pick disease type C in neonatal cholestasis at a North American center. J. Pediatr. Gastroenterol. Nutrit. 2002; 35: 44–50
Zhou, H., Linke, R.P., Schaefer, H.E., Möbius, W., Pfeifer, U.: Progressive liver failure in a patient with adult Niemann-Pick disease associated with generalized AL amyloidosis. Virchows Arch. 1995; 426: 635–639
Mucoviscidosis
Akata, D., Akhan, O.: Liver manifestations of cystic fibrosis (review). Eur. J. Radiol. 2007; 61: 11–17
Brigman, C., Feranchak, A.: Liver involvement in cystic fibrosis. Curr. Treat. Opin. Gastroenterol. 2006; 9: 484–496
Colombo, C., Battezzati, P.M., Podda, M., Bettinardi, N., Giunta, A.: Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double blind multicenter trial. Hepatology 1996; 23: 1484–1490
Colombo, C., Battezzati, P.M., Crosignani, A., Morabito, A., Constantini, D., Padoan, R., Giunta, A.: Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 2002; 36: 1374–1382
Couetil, J.P., Houssin, D.P., Dousset, B.E., Chevalier, P.G., Guinvarch, A., Loumet, D., Achkar, A., Carpentier, A.F.: Combined heart-lung-liver, double lung-liver, and isolated liver transplantation for cystic fibrosis in children. Transpl. Int. 1997; 19: 33–39
Dray-Charrier, N., Paul, A., Veissiere, D., Mergey, M., Scoazec, J.-Y., Chapeau, J., Brahimi-Horn, C., Housset, C.: Expression of cystic fibrosis transmembrane conductance regulator in human gallbladder epithelial cells. Lab. Invest. 1995; 73: 828–836
Gelman, M.S., Kopito, R.R.: Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis (review). J. Clin. Invest. 2002; 110: 1591–1597
Hulterantz, R., Mengarelli, S., Strandvik, B.: Morphological findings in the liver of children with cystic fibrosis: a light and electron microscopical study. Hepatology 1986; 6: 881–889
Lindblad, A., Glaumann, H., Strandvik, B.: Natural history of liver disease in cystic fibrosis. Hepatology 1999; 30: 1151–1158
O’Connor, P.J., Southern, K.W., Bowler, I.M., Irving, H.C., Robinson, P.J., Littlewood, J.M.: The role of hepatobiliary scintigraphy in cystic fibrosis. Hepatology 1996; 23: 281–287
Strandvik, B., Hultcrantz, R.: Liver function and morphology during long-term fatty acid supplementation in cystic fibrosis. Liver 1994; 14: 32–36
Williams, S.G.J., Evanson, J.E., Hodgson, M.E., Boultbee, J.E., Westaby, D.: An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis. J. Hepatol. 1995; 22: 513–521
Yang, Y., Raper, S.E., Cohn, J.A., Engelhardt, J.F., Wilson, J.M.: An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer. Proc. Nat. Acad. Sci. USA 1993; 90: 4601–4605
Zellweger’s syndrome
Danks, D.M., Tippett, P., Adams, C., Campbell, P.: Cerebro-hepatorenal syndrome of Zellweger. J. Pediatr. 1975; 86: 382–387
Eyssen, H., Eggermont, E., van Eldere, J., Jaeken, J., Parmentier, G., Janssen, G.: Bile acid abnormalities and the diagnosis of cerebro-hepato-renal syndrome (Zellweger’s syndrome). Acta Paediatr. Scand. 1985; 74: 539–544
Mathis, R.K., Watkins, J.B., van Szczepanik-van Leeuwen, P., Lott, I.T.: Liver in the cerebro-hepato-renal syndrome: defective bile acid synthesis and abnormal mitochondria. Gastroenterology 1980; 79: 1311–1317
Moser, A.E., Sing, I., Bown, F.R., Solish, G.I., Kelley, R.I., Benke, P.J., Moser, H.W.: The cerebrohepatorenal (Zellweger) syndrome. Increased levels and impaired degradation of very-long-chain fatty acids and their use in prenatal diagnosis. New Engl. J. Med. 1984; 310: 1141–1146
Santos, M.J., Moser, A.B., Drwinga, H., Moser, H.W., Lazarow, P.B.: Analysis of peroxisomes in lymphoblasts: Zellweger’s syndrome and a patient with a deletion in chromosome 7. Pediatr. Res. 1993; 33: 441–444
Porphyrias
Andant, C., Puy, H., Bogard, C., Faivre, J., Soulé, J.C., Nordmann, Y., Deybach, J.C.: Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J. Hepatol. 2000; 32: 933–939
Andersson, C., Thunell, S., Floderus, Y., Forsell, C., Lundin G., Anvret, M., Lannfelt, L., Wetterberg, L., Lithner, F.: Diagnosis of acute intermittent porphyria in northern Sweden: an evaluation of mutation analysis and biochemical methods. J. Intern. Med. 1995; 237: 301–308
Andersson, C., Innala, E., Backstrom, T.: Acute intermittent porphyria in women: clinical expression, use and experience of exogenous hormones. A population-based study in northern Sweden. J. Intern. Med. 2003; 254: 176–183
Bjersing, L., Andersson, C., Lithner, F.: Hepatocellular carcinoma in patients from northern Sweden with acute intermittent porphyria: morphology and mutations. Canc. Epidem. Biomark. Prev. 1996; 5: 393–397
Blonmer, J.R., Rank, J.M., Pavne, W.D., Snover, D.C., Sharp, H.L., Zwiener, R.J., Carithers, R.L.: Follow-up after liver transplantation for protoporphyric liver disease. Liver Transplant. Surg. 1996; 4: 269–275
Bloomer, J.R.: Liver metabolism of porphyrins and haem. J. Gastroenterol. Hepatol. 1998; 13: 324–329
Bonkovsky, H.L., Schned, A.R.: Fatal liver failure in protoporphyria. Synergism between ethanol excess and the genetic defect. Gastroenterology 1986; 90: 191–201
Bonkovsky, H.L., Barnard, G.F.: Diagnosis of porphyric syndromes: a practical approach in the era of molecular biology. Semin. Liver Dis. 1998; 18: 57–65
Brenner, D.A., Didier, J.M., Frazier, F., Christensen, S.R., Evans, G.A., Dailey, H.A.: A molecular defect in human protoporphyria. Amer. J. Hum. Genet. 1992; 50: 1203–1210
Bruguera, M.: Liver involvement in porphyria. Semin. Dermatol. 1986; 5: 178–185
Cox, T.M., Alexander, G.J.M., Sarkany, R.P.E.: Protoporphyria. Semin. Liver Dis. 1998; 18: 85–93
Da Silva, V., Simonin, S., Deybach, J.C., Puy, H., Nordmann, Y.: Variegate porphyria: diagnostic value of fluometric scanning of plasma porphyrins. Clin. Chim. Acta 1995; 238: 163–168
Doss, M.O., Frank, M.: Hepatobiliary implications and complications in protoporphyria: a 20-years study. J. Clin. Biochem. 1989; 22: 223–239
Doss, M.O., Kühnel, A., Groß, U., Sieg, I.: Hepatic porphyrias and alcohol. Med. Klin. 1999; 94: 314–328
Doss, M.O., Gross, U., Puy, H., Doss, M., Kuhnel, A., Jacob, K., Deybach, J.C., Nordmann, Y.: Coexistence of hereditary coproporphyria and porphyria cutanea tarda: a new type of a dual porphyria. Med. Klin. 2002; 97: 1–5
Egger, N.G., Goeger, D.E., Payne, D.A., Miskovsky, E.P., Weinman, S.A., Anderson, K.E.: Porphyria cutanea tarda. Multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphy rinogen decarboxy lase deficiency. Dig. Dis. Sci. 2002; 47: 419–426
Elder, G.H.: Porphyria cutanea tarda. Semin. Liver Dis. 1998; 18: 67–76
Fargion, S., Sergi, C., Bissoli, F., Fracanzani, A.L., Suigo, E., Carrazzone, A., Roberto, C., Cappellini, M.D., Fiorelli, G.: Lack of association between porphyria cutanea tarda and α1 deficiency. Europ. J. Gastroenterol. Hepatol. 1996; 8: 387–391
Fargion, S., Fracanzani, A.L.: Prevalence of hepatitis C virus infection in porphyria cutanea tarda. J. hepatol. 2003; 39: 635–638
Ferri, C., Baicchi, U., La Civita, L., Greco, F., Zigneco, A.L., Manns, M.P.: Hepatitis C virus-related autoimmunity in patients with porphyria cutanea tarda. Eur. J. Clin. Invest. 1993; 23: 851–855
Gisbert, J.P., Garcia-Buey, L., Pajares, J.M., Moreno-Otero, R.: Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J. Hepatol. 2003; 39: 620–627
Gorchein, A.: Drug treatment in acute porphyria. Brit. J. Clin. Pharmacol. 1997; 44: 427–434
Grandchamp, B., Puy, H., Lamoril, J., Deybach, J.C., Nordmann, Y.: Review: Molecular pathogenesis of hepatic acute porphyrias. J. Gastroenterol. Hepatol. 1996; 11: 1046–1052
Groß, U., Frank, M., Doss, M.O.: Hepatic complications of erythropoietic protoporphyria. Photoderm. Photoimmun. Photomed. 1998; 14: 52–57
Horie, Y., Norimoto, M., Tajima, F., Sasaki, H., Nanba, E., Kawasaki, H.: Clinical usefulness of cimetidine treatment for acute relapse in intermittend porphyria. Clin. Chim. Acta 1995; 234: 171–175
Ishibashi, A., Ogata, R., Sakisaka, S., Kumashiro, R., Koga, Y., Mitsuyama, K., Kuromatsu, R., Uchimura, Y., Ijuin, H., Tanaka, K., Iwao, T., Ishii, K., Sata, M., Inoue, Y., Kin, Y., Oizumi, K., Nishida, H., Imaizumi, T., Tanikawa, K.: Erythropoietic protoporphyria with fatal failure. J. Gastroenterol. 1999; 34: 405–409
Kauppinen, R., Mustajoki, P.: Acute porphyria and hepatocellular carcinoma. Brit. J. Cancer 1988; 57: 117–120
Kauppinen, R., Mustajoki, P.: Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine 1992; 71: 1–13
Kauppinen, R., Timonen, K., Mustajoki, P.: Treatment of the porphyrias. Ann. Med. 1994; 26: 31–38
Logan, G.M., Weimer, M.K., Ellefson, M., Pierach, C.A., Bloomer, J.R.: Bile porphyrin analysis in the evaluation of variegate porphyria. New Engl. J. Med. 1991; 324: 1408–1411
MacDonald, D.M., Germain, D., Perrot, H.: The histopathology and ultrastructure of liver disease in erythropoetic protoporphyria. Brit. J. Dermatol. 1981; 104: 7–17
Manzione, N.C., Wolkoff, A.W., Sassa, S.: Development of porphyria cutanea tarda after treatment with cyclophosphamide. Gastroenterology 1988; 95: 1119–1122
Moore, M.R.: Biochemistry of porphyria. Int. J. Biochem. 1993; 25: 1353–1368.
Mustajoki, P., Nordmann, Y.: Early administration of heme arginate for acute porphyric attacks. Arch. Intern. Med. 1993; 153: 2004–2008
Navas, S., Bosch, O., Castillo, I., Marriott, E., Carreno, V.: Porphyria cutanea tarda and hepatitis C and B viruses infection: a retrospective study. Hepatology 1995; 21: 279–284
Poh-Fitzpatrick, M.B.: Clinical features of the porphyrias. Clin. Dermatol 1998; 16: 251–264
Rank, J.M., Carithers, R., Bloomer, J.: Evidence for neurological dysfunction in end-stage protoporphyric liver disease. Hepatology 1993; 18: 1404–1409
Salata, H., Cortes, J.M., Enriquez de Salamanca, R., Oliva, H., Castro, A., Kusak, E., Carreno, V., Hernandez Guio, C.: Porphyria cutanea tarda and hepatocellular carcinoma. Frequency of occurrence and related factors. J. Hepatol. 1985; 1: 477–487
Samuel, D., Boboc, B., Bernuau, J., Bismuth, H., Benhamou, J.P.: Liver transplantation for protoporphyria. Evidence for the predominent role of the erythropoetic tissue in protoporphyria overproduction. Gastroenterology 1988; 95: 816–819
Sarkany, R.P.E., Alexander, G.J.M., Cox, T.M.: Recessive inheritance of erythropoietic protoporphyria with liver failure. Lancet 1994; 343: 1394–1396
Sassa, S., Kappas, A.: Molecular aspects of the inherited porphyrias. J. Intern. Med. 2000; 247: 169–178
Scarlett, Y.V., Brenner, D.A.: Porphyrias. J. Clin. Gastroenterol. 1998; 27: 192–198
Siersema, P.D., Rademakers, L.H.P.M., Cleton, M.I., ten Kate, F.J.W., de Bruijn, W.C., Marx, J.J.M., Wilson, H.J.P.: The difference in liver pathology between sporadic and familial forms of porphyria cutanea tarda: the role of iron. J. Hepatol. 1995; 23: 259–267
Stockinger, L.: Elektronenmikroskopische Befunde bei Leberbiopsien bei Porphyria cutanea tarda. Wien. Zschr. Inn. Med 1996; 47: 459–465
Tefferi, A., Colgan, J.P., Solberg, L.A.: Acute porphyrias: diagnosis and management. Mayo Clin. Proc. 1994; 69: 991–995
Tenhunen, R., Mustajoki, P.: Acute porphyria: treatment with heme. Semin. Liver Dis. 1998; 18: 53–55
Toback, A.C., Sassa, S., Poh-Fitzpatrick, M.B., Schechter, J., Zaider, E., Harber, L.C., Kappas, A.: Hepatoerythropoietic porphyria: clinical, biochemical, and enzymatic studies in a three-generation family lineage. New Engl. J. Med. 1987; 316: 645–650
Todd, D.J.: Molecular genetics of erythropoietic protoporphyria. Photoderm. Photoimmun. Photomed. 1998; 14: 70–73
Verneuil de, H., Bourgeois, F., de Rooij, F., Siersema, P.D., Wilson, J.H., Grandchamp, B., Nordmann, Y.: Characterization of a new mutation (R 292 G) and a deletion at the human uroporphyrinogen decarboxylase locus in two patients with hepatoerythropoietic porphyria. Hum. Genet. 1992; 89: 548–552
Wagner, S., Doss, M.O., Wittekind, C., Bäcker, U., Meessen, D., Schmidt, F.W.: Erythrohepatische Protoporphyrie mit rasch progredienter Leberzirrhose. Dtsch. Med. Wschr. 1989; 114: 1837–1841
Wassif, W.S., Deacon, A.C., Floderus, Y., Thunell, S., Peters, T.J.: Acute intermittent porphyria: diagnostic conundrums. Eur. J. Clin. Chem. Clin. Biochem. 1994; 32: 915–921
Wells, M.M., Golitz, L.E., Bender, B.J.: Erythropoietic protoporphyria with hepatic cirrhosis. Arch. Dermatol. 1980; 116: 429–432
Wilson’s disease
Akil, M., Brewer, G.J.: Psychiatric and behavioral abnormalities in Wilson’s disease. Adv. Neurol. 1995; 65: 171–178
Ala, A., Walker, A.P., Ashkan, K., Dooley, J.S., Schilsky, M.L.: Wilson’s disease. Lancet 2007; 369: 397–408
Akpinar, E., Akhan, O.: Liver imaging findings of Wilson’s disease (review). Eur. J. Radiol. 2007; 61: 25–32
Badii, M., Wong, H., Steinbrecher, U.P., Freeman, H.J.: Wilson’s disease in an elderly patient. Can. J. Gastroenterol. 1995; 9: 78–80
Bearn, A.G., McKusick, V.A.: Azure lunulae. An unusual change in the fingernails in two patients with hepatolenticular degeneration (Wilson’s disease). J. Amer. Med. Ass. 1958; 166: 904–906
Bellary, S.V., van Thiel, D.H.: Wilson’s disease: a diagnosis made in two individuals greater than 40 years of age. J. Okla. State Med. Assoc 1993; 86: 441–444
Bellary, S.V., Hassanein, T., van Thiel, D.H.: Liver transplantation for Wilson’s disease. J. Hepatol. 1995; 23: 373–381
Bowcock, A.M., Farrer, L.A., Herbert, J.M., Agger, M., Sternlieb, I., Scheinberg, I.H., Buys, C.H.C.M., Scheffer, H., Frydman, M., Chajek-Saul, T., Bonne-Tamir, B., Caralli-Sforza, L.L.: Eight closely linked loci place the Wilson’s disease locus within 13q14-q21. Amer. J. Human. Genet. 1988; 43: 664–674
Brewer, G.J.: Practical recommendations and new therapies for Wilsons’s disease. Drugs 1995; 50: 240–249
Bull, P.C., Thomas, G.R., Rommens, J.M., Forbes, J.R., Wilson Cox, D.: The Wilson’s disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat. Genet. 1993; 5: 327–337
Cairns, J.E., Williams, H.P., Walshe, J.M.: “Sunflower cataract” in Wilson’s disease. Brit. Med. J. 1969/III: 95–96
Carpenter, T.O., Carnes, D.L.jr., Anast, C.S.: Hypoparathyroidism in Wilson’s disease. New Engl. J. Med. 1983; 309: 873–877
Cauza, E., Maier-Dobersberger, T., Polli, C., Kaserer, K., Kramer, L., Ferenci, P.: Screening for Wilson’s disease in patients with liver diseases by serum ceruloplasmin. J. Hepatol. 1997; 27: 358–362
Dameron, C.T., Harrison, M.D.: Mechanisms for protection against copper toxicity. Amer. J. Clin. Nutr. 1998; 67 (Suppl.): 1091–1097
Davis, W., Chowrimootoo, G.F.E., Seymour, C.A.: Defective biliary copper excretion in Wilson’s disease: the role of caeruloplasmin. Eur. J. Clin. Invest. 1996; 26: 893–901
De Andrade, D.R., Fujito Neto, F.G., Vieira, G.S., Tiberio, I.F., Warth, M.P., Carlich, I.: Acute hemolytic crisis followed by fulminant hepatic failure with fatal outcome, as a first clinical manifestation of Wilson’s disease. Rev. Hosp. Clin. Fac. Med. Sao Paulo 1994; 49: 69–75
Degenhardt, S., Blomhard, G., Hefter, H., Kreuzpaintner, G., Lindemann, W., Lobeck, H., Schnaith, E., Stremmel, W., Grabensee, B.: Hamolytische Krise mit Leberversagen als Erstmanifestation eines Morbus Wilson. Dtsch. Med. Wschr. 1994; 119: 1421–1426
Duvoux, C.: Severe hepatitis during Wilson’s disease. Gastroenterol. Clin. Biol. 2004; 28 (Suppl. 5): 202–205
Erhardt, A., Hoffmann, A., Hefter, H., Häussinger, D.: HFE gene mutations and iron metabolism in Wilson’s disease. Liver 2002; 22: 474–478
Fleischer, B.: Zwei weitere Fälle von grünlicher Verfärbung der Kornea. Klin. Mbl. Augenheilk. 1903; 41: 489–491
Fleischer, B.: Die periphere braungrünliche Hornhautverfärbung als Symptom einer eigenartigen Allgemeinerkrankung. Münch. Med. Wschr. 1909; 56: 1120–1123
Gitlin, J.D.: Wilson disease (review). Gastroenterology 2003; 125: 1868–1877
Gow, P.J., Smallwood, R.A., Angus, P.W., Smith, A.L., Wall, A.J., Sewell, R.B.: Diagnosis of Wilson’s disease: an experience over three decades. Gut 2000; 46: 415–419
Gu, M., Cooper, J.M., Butler, P., Walker, A.P., Mistry, P.K., Dooley, J.S., Schapira, A.H.V.: Oxidative-phosphorylation defects in liver of patients with Wilson’s disease. Lancet 2000; 356: 469–474
Hoogenraad, T.U., van den Hamer, C.J.A., van Hattum, J.: Effective treatment of Wilson’s disease with oral zinc sulphate: two case reports. Brit. Med. J. 1984; 289: 273–276
Hoppe, B., Neuhaus, T., Superti-Furga, A., Forster, I., Leumann, E.: Hypercalciuria and nephrocalcinosis. a feature of Wilson’s disease. Nephron 1993; 65: 460–462
Houwen, R.H.J., Roberts, E.A., Thomas, G.R., Cox, D.W.: DNA markers for the diagnosis of Wilson’s disease. J. Hepatol. 1993; 17: 269–276
Huster, D., Hoppert, M., Lutsenko, S., Zinke, J., Lehmann, C., Mössner, J., Berr, F., Caca, K.: Defective cellular localization of mutant ATP 7B in Wilson’s disease patients and hepatoma cell lines. Gastroenterology 2003; 124: 335–345
Kayser, B.: Über einen Fall von angeborener grünlicher Verfärbung der Cornea. Klin. Mbl. Augenheilk. 1902; 40: 22–25
Lutsenko, S., Barnes, N.L., Bartee, M.Y., Dmitriew, O.Y.: Function and regulation of human copper-transporting ATPases. Physiol. Rev. 2007; 87: 1011–1046
Magalhaes, A.C., Caramelli, P., Menezes, J.R, Lo, L.S., Bacheschi, L.A., Barbosa, E.R., Rosenberg, L.A., Magalhaes, A.: Wilson’s disease: MRI with clinical correlation. Neuroradiology 1994; 36: 97–100
Maier-Dobersberger, T., Mannhalter, C., Rack, S., Granditsch, G., Kaserer, K., Korninger, L., Steindl, P., Gangl, A., Ferenci, P.: Diagnosis of Wilson’s disease in an asymptomatic sibling by DNA linkage analysis. Gastroenterology 1995; 109: 2015–2018
Mason, A.L., Marsh, W., Alpers, D.: Intractable neurological Wilson’s disease treated with orthotopic liver transplantation. Dig. Dis. Sci. 1992; 38: 1746–1750
McCullough, A.J., Fleming, C.R., Thistle, J.L., Baldus, W.P., Ludwig, J., McCall, J.T., Dickson, E.R.: Diagnosis of Wilson’s disease presenting as fulminant hepatic failure. Gastroenterology 1983; 84: 161–167
Menerey, K.A., Eider, W., Brewer, G.J., Braunstein, E.M., Schumacher, H.R., Fox, I.: The arthropathy of Wilson’s disease: clinical and pathological features. J. Rheumatol. 1988; 15: 331–337
Merle, U., Schaefer, M., Ferencsi, P., Stremmel, W.: Clinical presentation, diagnosis and long-term outcome of Wilson’s disease. A cohort study. Gut 2007; 56: 115–120
Myers, B.M., Prendergast, F.G., Holman, R., Kuntz, S.M., LaRusso, N.F.: Alterations in hepatocyte lysosomes in experimental hepatic copper overload in rats. Gastroenterology 1993; 105: 1814–1823
Nakada, S.Y., Brown, M.R., Rabinowitz, R.: Wilson’s disease presenting as symptomatic urolithiasis: a case report and review of literature. J. Urol. 1994; 152: 978–979
Nagasaka, H., Inoue, I., Inui, A., Komatsu, H., Sogo, T., Murayama, K., Murakami, T., Yorifugi, T., Asayama, K., Katayama, S., Uemoto, S., Kobayashi, K., Takayanagi, M., Fujisawa, T., Tsukahara, H.: Relationship between oxidative stress and antioxidant systems in the liver of patients with Wilson’s disease: Hepatic manifestation in Wilson’s disease as a consequence of augmented oxidative stress Pediatr. Res 2006; 60: 472–477
Nazer, H., Ede, R.J., Mowat, A.P., Williams, R.: Wilson’s disease: clinical presentation and use of prognostic index. Gut 1986; 27: 1377–1381
Okada, T., Morise, T., Takeda, Y., Mabuchi, H.: A new variant deletion of a copper-transporting P-type ATPase gene found in patients with Wilson’s disease presenting with fulminant hepatic failure. J. Gastroenterol. 2000; 35:278–283
Petrukhin, K., Fischer, S.G., Pirastu, M., Tanzi, R.E., Chernov, I., Devoto, M., Brzustowicz, L.M., Cayanis, E., Vitale, E., Russo, J.J., Matseoane, D., Boukhgalter, B., Wasco, W., Figus, A.L., Loudianos, J., Cao, A., Sternlieb, I., Evgrafov, O., Parano, E., Pavone, L., Warburton, D., Ott, J., Penchaszadeh, G.K., Scheinberg, I.H., Gilliam, T.C.: Mapping, cloning and genetic characterization of the region containing the Wilson’s disease gene. Nat. Genet. 1993; 5: 338–343
Polio, J., Enriquez, R.E., Chow, A., Wood, W:M., Atterbury, C.E.: Hepatocellular carcinoma in Wilson’s disease: Case report and review of the literature. J. Clin. Gastroenterol. 1989; 11: 220–224
Polson, R.J., Rolles, K., Calne, R.Y., Williams, R., Madsden, D.: Reversal of severe neurological manifestations of Wilson’s disease following orthotopic liver transplantation. Quart. J. Med. 1987; 64: 685–691
Probst, A., Propst, T., Feichtinger, H., Judmaier, G., Willeit, J., Vogel, W.: Copper-induced acute rhabdomyolysis in Wilson’s disease. Gastroenterology 1995; 108: 885–887
Rakela, J., Kurtz, S.B., McCarthy, J.T., Ludwig, J., Ascher, N.L., Bloomer, J.R., Claus, P.L.: Fulminant Wilson’s disease treated with post-dilution hemofiltration and orthotopic liver transplantation. Gastroenterology, 1986; 90: 2004–2007
Roberts, E.A., Schilsky, M.L.: A practice guideline on Wilson disease. Hepatology 2003; 37: 1475–1492
Roche-Sicot, J., Benhamou, J.-P.: Acute intravascular hemolysis and acute liver failure associated as a first manifestation of Wilson’s disease. Ann. Intern. Med. 1977; 86: 301–303
Roh, J.K., Lee, T.G., Wie, B.A., Lee, S.B., Park, S.H., Chang, K.H.: Initial and follow-up brain MRI findings and correlation with the clinical course in Wilson’s disease. Neurology 1994; 44: 1064–1068
Rossaro, L., Sturniolo, G.C., Giacon, G., Montino, M.C., Lecis, P.E., Schade, R.R., Corazza, G.R., Trevisan, C.: Zinc therapy in Wilson’s disease: observations in five patients. Amer. J. Gastroenterol. 1990: 85: 665–668
Sallie, R., Katsiyiannakis, L., Baldwin, D., Davies, S., O’Grady, J., Mowat, A., Mieli-Vergani, G., Williams, R.: Failure of simple biochemical index to reliably differentiate fulminant Wilson’s disease from other causes of fulminant liver failure. Hepatology 1992; 16: 1206–1211
Scheinberg, I.H., Jaffe, M.E., Sternlieb, I.: The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson’s disease. New Engl. J. Med. 1987; 317: 209–213
Schilsky, M.L.: Wilson disease: genetic basis of copper toxicity and natural history. Semin. Liver Dis. 1996; 16: 83–95
Schoen, R.E., Sternlieh, I.: Clinical aspects of Wilson’s disease. Amer. J. Gastroenterol. 1990; 85; 1453–1457
Schumacher, G., Platz, K.P., Mueller, A.R., Neuhaus, R., Steinmüller, T., Bechstein, W.O., Becker, M., Luck, W., Schuelke, M., Neuhaus, P.: Liver transplantation: treatment of choice for hepatic and neurological manifestation of Wilson’s disease. Clin. Transplant. 1997; 11: 217–224
Sen, S., Felldin, M., Steiner, C., Larsson, B., Gillett, G.T., Olausson, M., Williams, R., Jalan, R.: Albumin dialysis and molecular adsorbents recirculating system (MARS) for acute Wilson’s disease (case report). Liver Transplant 2002; 8: 962–967
Shaver, W.A., Bhatt, H., Combes, B.: Low serum alkaline phosphatase activity in Wilson’s disease. Hepatology 1986; 6: 859–863
Stampfl, D.A., Munoz, S.J., Moritz, M.J., Rubin, R., Armenti, V.T., Jarrell, B.E., Maddrey, W.C.: Heterotopic liver transplantation for fulminant Wilson’s disease. Gastroenterology 1990; 99: 1834–1836
Starosta-Rubinstein, S., Young, A.B., Kluin, K., Hill, G., Aisen, A.M., Gabrielsen, T., Brewer, G.J.: Clinical assessment of 31 patients with Wilson’s disease Correlations with structural changes on magnetic resonance imaging. Arch. Neurol. 1987; 44: 365–370
Sternlieb, I.: Wilson’s disease and pregnancy. Hepatology 2000; 31: 531–532
Strand, S., Hofmann, W.J., Grambihler, A., Hug, H., Volkmann, M., Otto, G., Wesch, H., Mariani, S.M., Hack, V., Stremmel, W., Krammer, P.H., Galle, P.R.: Hepatic failure and liver cell damage in acute Wilson’s disease involve CD 95 (APO-1/Fas)-mediated apoptosis. Nat. Med. 1998; 4: 588–593
Stremmel, W., Meyerrose, K.-W., Niederau, C., Hefter, H., Kreuzpainter, G., Strohmeyer, G.: Wilson’s disease: clinical presentation, treatment, and survival. Ann. Intern. Med. 1991; 115: 720–726
Stromeyer, F.W., Ishak, K.G.: Histology of the liver in Wilson’s disease. A study in 34 cases. Amer. J. Clin. Pathol. 1980; 73: 12–24
Tao, T.Y., Gitlin, J.D.: Hepatic copper metabolism: insights from genetic disease. Hepatology 2003; 37: 1241–1247
Terajima, H., Tanaka, K., Okajima, K., Inomata, Y., Yamaoka, Y.: Timing of transplantation and donor selection in living-related liver transplantation for fulminant Wilson’s disease. Transplant. Proc. 1995; 27: 1177–1178
Thomas, G.R., Forbes, J.R, Roberts, E.A., Walshe, J.M., Cox, D.W.: The Wilson’s disease gene: spectrum of mutations and their consequences. Nat. Genet. 1995; 9: 210–210
Turnland, J.R.: Human whole-body copper metabolism. Amer. J. Clin. Nutr. 1998; 67: 960–964
Veen, C., van den Hamer, C.J.A., de Leeuw, P.W.: Zinc sulphate therapy for Wilson’s disease after acute deterioration during treatment with low-dose D-penicillamine. J. Intern. Med. 1991; 229: 549–552.
Walshe, J.M.: Treatment of Wilson’s disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1982/I: 643–647
Walshe, J.M., Waldenstrom, E., Sams, V., Nordlinder, H., Westermark, K.: Abdominal malignancies in patients with Wilson’s disease. Quart. J. Med. 2003; 96: 657–662
Wieber, D.O., Wilson, D.M., McLeod, R.A., Goldstein, N.P.: Renal stones in Wilson’s disease. Am. J. Med. 1979; 67: 249–254
Wilkinson, M.L., Portmann, B., Williams, R.: Wilson’s disease and hepatocellular carcinoma: Possible protective role of copper. Gut 1983; 24: 767–771
Wilson, S.A.K.: Progressive lenticular degeneration: A familiar nervous disease associated with cirrhosis of the liver. Brain 1912; 34: 295–509
Yamaguchi, Y., Heiny, M.E., Gitlin, J.D.: Isolation and characterization of a human liver cDNA as a candidate gene for Wilson’s disease. Biochem. Biophys. Res. Commun. 1993; 197: 271–277
Yang, F., Naylor, S.L., Lum, J.B., Cutshaw, St., McCombs, J.L., Haberhaus, K.H., McGill, J.R., Adrian, G.S., Moore, J.L., Barnett, D.R., Bowman, B.H.: Characterisation, mapping and expression of the human caeruloplasmin gene. Proc. Natl. Acad. Sci. USA 1986; 83: 3257–3261
Indian childhood cirrhosis
Baker, A., Gormally, S., Saxena, R., Baldwin, D., Drumm, B., Bonham, J., Portmann, B., Mowat, A.P.: Copper-associated liver disease in childhood. J. Hepatol. 1995; 23: 538–543
Bavdekar, A.R., Bhave, S.A., Pradhan, A.M., Pandit, A.N., Tanner, M.S.: Long term survival in Indian childhood cirrhosis treated with D-penicillamine. Arch. Dis. Childh. 1996; 74: 32–35
Haemochromatosis
Adams, P.C., Searle, J.: Neonatal hemochromatosis: a case and review of the literature. Amer. J. Gastroenterol. 1988; 83: 422–425
Adams, P.C., Gregor, J.: Hemochromatosis and yersiniosis. Canad. J. Gastroenterol. 1990; 4: 160–162
Adams, P.C., Deugnier, Y., Moirand, R., Brissot, P.: The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997; 25: 162–166
Adams, P.C., Kertesz, A.E., McLaren, C.E., Barr, R., Bamford, A., Chakrabarti, S.: Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors. Hepatology 2000; 31: 1160–1164
Aellen, P., Guerne, P.-A., Zenagui, D., Vischer, T.L.: Ľarthropathie de ľhemochromatose: manifestation souvent inaugurale de la maladie. Schweiz. Med. Wschr. 1992; 122: 842–849
Alustiza, J.M., Artetxe, J., Castiella, A., Agirre, C., Emparanza, P., Otazua, P., Garcia-Bengoechea, M., Barrio, J., Mujica, F., Recondo, J.A.: MR quantification of hepatic iron concentration. Radiology 2004; 230: 479–484
Alustiza, J.M., Castiella, A., de Juan, M.D., Emparanza, J.I., Artetxe, J., Uranga, M.: Iron overload in the liver: diagnostic and quantification. Eur. J. Radiol. 2007; 61: 499–506
Baer, D.M., Simons, J.L., Staples, R.L., Rumore, G.J., Morton, C.J.: Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older. Amer. J. Med. 1995; 98: 464–468
Balan, V., Baldus, W., Fairbanks, V., Michels, V., Burritt, M., Klee, G.: Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients. Gastroenterology 1994; 107: 453–459
Beutler, E., Felitti, V., Gelbart, T., Ho, N.: The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann. Intern. Med. 2000; 133: 329–337
Bhavnani, M., Lloyd, D., Bhattacharyya, A., Marples, J., Elton, P., Worwood, M.: Screening for genetic hemochromatosis in blood samples with raised alanine aminotransferase. Gut 2000; 46: 707–710
Blisard, K.S., Bartow, S.A.: Neonatal hemochromatosis. Hum. Path. 1986; 17: 376–383
Blumberg, R.S., Chopra, S., Ibrahim, R., Crawford, J., Farraye, F.A., Zeldis, J.B., Berman, M.D.: Primary hepatocellular carcinoma in idiopathic hemochromatosis after reversal of cirrhosis. Gastroenterology 1988; 95: 1399–1402
Boige, V., Castera, L., de Roux, N., Ganne-Carrie, N., Ducot, B., Pelletier, G., Beaugrand, M., Buffet, C.: Lack of association between HFE gene mutations and hepatocellular carcinoma in patients with cirrhosis. Gut 2003; 52: 1178–1181
Bonkovsky, H.L., Rubin, R.B., Cable, E.E., Davidoff, A., Pels Rijcken, T.H., Stark, D.D.: Hepatic iron concentration: noninvasive estimation by means of MR imaging techniques. Radiology 1999; 212: 227–234
Candell-Riera, J., Seres, L., Gonzales, J.B., Batille, J., Permanyer-Miralda, G., Garcia-del-Castillo, H., Soler-Soler, J.: Cardiac hemochromatosis: beneficial effects of iron removal therapy. Amer. J. Cardiol. 1983; 52: 824–829
Crawford, D.H.G., Leggett, B.A., Powell, L.W.: Haemochromatosis. Baill. Clin. Gastroenterol. 1998; 12: 209–225
Cremonesi, P., Acebron, A., Raja, K.B., Simpson, R.J.: Iron absorption: Biochemical and molecular insights into the importance of iron species for intestinal uptake. Pharm. Toxicol. 2002; 91: 97–102
Cundy, T., Butler, J., Bomford, A., Williams, R.: Reversibility of hypogonatotrophic hypogonadism associated with genetic haemochromatosis. Clin. Endocrin. 1993; 38: 617–620
Davis, W.D., Arrowsmith, W.R.: The effect of repeated bleeding in hemochromatosis. J. Lab. Clin. Med. 1950; 36: 814–815
De Bont, B., Walker, A.C., Carter, R.F., Oldfield, R.K., Davidson, G.P.: Idiopathic hemochromatosis presenting as acute hepatitis. J. Pediatr. 1987; 110: 431–434
Deugnier, Y.M., Loréal, O., Turlin, B., Guyader, D., Jouanolle, H., Moirand, R., Jacquelinet, C., Brissot, P.: Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations. Gastroenterology 1992; 102: 2050–2059
Deugnier, Y.M., Guyader, D., Crantock, L., Lopez, J.-M., Turlin, B., Yaouanq, J., Jouanolle, H., Campion, J.-P., Launois, B., Halliday, J.W., Powell, L.W., Brissot, P.: Primary liver cancer in genetic hemochromatosis: a clinical pathological and pathogenetic study of 54 cases. Gastroenterology 1993; 104: 228–234
Disler, P.B., Lynch, S.R., Charlton, R.W., Torrance, J.D., Bothwell, T.H., Walker, R.B., Mayet, F.: The effect of tea on iron absorption. Gut 1975; 16: 193–200
Dugast, I.J., Papadopoulus, P., Zappone, E., Jones, C., Theriault, K., Handelman, G.J., Benarous, R., Drysdale, J.W.: Identification of two human ferritin H genes on the short arm of chromosome 6. Genomics 1990; 6: 204–211
Edwards, C.Q., Griffen, L.M., Dadone, M.M., Skolnick, M.H., Kushner, J.P.: Mapping the locus for hereditary hemochromatosis: localization between HLA-B and HLA-A. Amer. J. Genet. 1986; 38: 805–811
Edwards, C.Q., Griffen, L.M., Goldgar, D., Drummond, C., Skolnick, M. Kushner, J.P.: Prevalence of hemochromatosis among 11 065 presumably healthy blood donors. New Engl. J. Med. 1988; 318: 1355–1362
Eijkelkamp, E.J., Yapp, T.R., Powell, L.W.: HFE-associated hereditary hemochromatosis. Can. J. Gastroenterol. 2000; 14: 121–125
Elmberg, M., Hultcrantz, R., Ekborn, A., Brandt, L., Olsson, R., Lindgren, S., Lööf, L., Stal, P., Wallerstedt, S., Almer, S., Sandberg-Gertzen, H., Askling, J.: Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003; 125: 1733–1741
Failla, M., Giannattasio, C., Piperno, A., Vergani, A., Grappiolo, A., Gentile, G., Meles, E., Mancia, G.: Radial artery wall alterations in genetic hemochromatosis before and after iron depletion therapy. Hepatology 2000; 32: 569–573
Fargion, S., Fracanzani, A.L., Piperno, A., Braga, M., D’Alba, R., Ronchi, G., Fiorelli, G.: Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology 1994; 20: 1426–1431
Farrell, F.J., Nguyen, M., Woodley, S., Imperial, J.C., Garcia-Kennedy, R., Man, K., Esquivel, C.O., Keeffe, E.B.: Outcome of liver transplantation in patients with hemochromatosis. Hepatology 1994; 20: 404–410
Fletcher, L.M., Halliday, J.W.: Haemochromatosis: understanding the mechanism of disease and implications for diagnosis and patient management following the recent cloning of novel genes involved in iron metabolism. J. Intern. Med. 2002; 251: 181–192
Fracanzani, A.L., Conte, D., Fraquelli, M., Taioli, E., Mattioli, M., Losco, A., Fargion, S.: Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001; 33: 647–651
Gandon, Y., Olivie, D., Guyader, D., Aube, C., Oberti, F., Sebille, V., Dlugnier, Y.: Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004; 363: 357–362
Grabhorn, E., Richter, A., Burdelski, M., Rogiers, X., Ganschow, R.: Neonatal hemochromatosis: Long-term experience with favorable outcome. Pediatrics 2006; 118: 2060–2065
Guayder, D., Gandou, Y., Robert, J.Y., Heautot, J.F., Jouanolle, H., Jacquelinet, C., Messner, M., Deugnier, Y., Brissot, P.: Magnetic resonance imaging and assessment of liver iron content in genetic hemochromatosis. J. Hepatol. 1992; 15: 304–308
Hardy, L., Hansen, J.L., Kushner, J.P., Knisely, A.S.: Neonatal hemochromatosis. Genetic analysis of transferrin-receptor, H-apoferritin, and L-apoferritin loci and of the human leukocyte antigen class I region. Amer. J. Pathol. 1990; 137: 149–153
Hsing, A.W., McLaughlin, J.K., Olsen, J.H., Mellemkjar, L., Wacholder, S., Fraumemi, J.F.Jr.: Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int. J. Cancer 1995; 60: 160–162
Hübscher, S.G.: Iron overload, inflammation and fibrosis in genetic haemochromatosis. (editorial). J. Hepatol. 2003; 38: 521–525
Jouanolle, A.M., Gandou, G., Jézéquel, P., Blayau, M., Campion, M.L., Yaouanq, J., Mosser, J., Fergelot, P., Chauvel, B., Bouric, P., Carn, G., Andrieux, N., Gicquel, I., Le Gall, J.-Y., David, V.: Haemochromatosis and HLA-H. Nat. Genet. 1996; 14: 251–252
Kaltwasser, J.P., Werner, E., Schalk, K., Hansen, C., Gottschalk, R., Seidl, C.: Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut 1998; 43: 699–704
Kelly, T.M., Edwards, C.Q., Meikle, A.W., Kushner, J.P.: Hypogonadism in hemochromatosis: reversal with iron depletion. Ann. Intern. Med. 1984; 101: 629–632
Kew, M.D.: Pathogenesis of hepatocellular carcinoma in hereditary hemochromatosis: occurrence in noncirrhotic liver. Hepatology 1990; 11: 1086–1087
Knisely, A.S., Mieli-Vergagni, G., Whitington, P.F.: Neonatal hemochromatosis. Gastroenterol. Clin. N. Amer. 2003; 32: 877–889
Lebron, J.A., Bennett, M.J., Vaughn, D.E., Chirino, A.J., Snow, P.M., Mintier, G.A., Feder, J.N., Bjorkman, P.J.: Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 1998; 93: 111–123
Ludwig, J., Batts, K.P., Moyer, T.P., Baldus, W.P., Fairbanks, V.F.: Liver biopsy diagnosis of homozygous hemochromatosis: A diagnostic algorithm. Mayo Clin. Proc. 1993; 68: 263–267
Macfarlane, J.D., Vreugdenhil, G.R., Doornbos, J., van der Voet, G.B.: Idiopathic haemochromatosis: magnetic resonance signal intensity ratios permit non-invasive diagnosis of low levels of iron overload. Netherl. J. Med. 1995; 47: 49–53
McCune, C.A., Ravine, D., Worwood, M., Jackson, H.A., Evans, H.M., Hutton, D.: Screening for hereditary haemochromatosis within families and beyond. Lancet 2003; 362: 1897–1898
McDonnell, S.M., Preston, B.L., Jewell, S.A., Barton, J.C., Edwards, C.Q., Adams, P.C., Yip, R.: A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Amer. J. Med. 1999; 106: 619–624
Melefors, Ö., Hentze, M.W.: Iron regulatory factor — the conductor of cellular iron regulation. Blood Rev. 1993; 7: 251–258
Morcos, M., Dubois, S., Bralet, M.P., Belghiti, J., Terris, B.: Primary liver carcinoma in genetic hemochromatosis reveals a broad histological spectrum. Amer. J. Clin. Path. 2001; 116: 738–743
Muiesan, P., Rela, M., Kane, P., Dawan, A., Baker, A., Ball, C., Mowat, A.P., Williams, R., Heaton, N.D.: Liver transplantation for neonatal haemochromatosis. Arch. Dis. Childh. 1995; 73: 178–180
Nairz, M., Weis, G.: Molecular and clinical aspects of iron homeostasis: from anemia to hemochromatosis. Wien. Klin. Wschr. 2006; 118: 442–462
Niederau, C., Fischer, R., Pürschel, A., Stremmel, W., Häussinger, D., Strohmeyer, G.: Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107–1119
Nielsen, P., Carpinteiro, S., Fischer, R., Cabeda, J.M., Porto, G., Gabbe, E.E.: Prevalence of the C282Y-and the H 63 D-mutations in the HFE-gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany. Brit. J. Haematol. 1999; 103: 842–845
Niemela, O., Parkkila, S., Britton, R.S., Brunt, E., Janney, C., Bacon, B.: Hepatic lipid peroxidation in hereditary hemochromatosis and alcoholic liver injury. J. Lab. Clin. Med. 1999; 133: 451–460
Olivieri, N.F., Berriman, A.M., Tyler, B.J., Davis, S.A., Francombe, W.H., Liu, P.P.: Reduction in tissue iron stores with a new regime of continuous ambulatory intravenous deferoxamine. Amer. J. Hematol. 1992; 41: 61–63
Olson, L.J., Edwards, W.D., Holmes, D.R.Jr., Miller, F.A.Jr., Nordstrom, L.A., Baldus, W.P.: Endomyocardial biopsy in hemochromatosis: clinicopathologic correlates in six cases. J. Amer. Coll. Cardiol. 1989; 13: 116–120
Olynyk, J., Hall, P., Sallie, R., Reed, W., Shilkin, K., Mackinnon, M.: Computerized measurement of iron in liver biopsies: a comparison with biochemical iron measurement. Hepatology 1990; 12: 26–30
Philpott, C.C.: Molecular aspects of iron absorption: insights into the role of HFE in hemochromatosis. Hepatology 2002; 35: 993–1001
Pillay, P., Tzoracoleftherakis, E., Tzakis, A.G., Kakizoe, S., van Thiel, D.H., Starzl, T.E.: Orthotopic liver transplantation for hemochromatosis. Transplant. Proc. 1991; 23: 1888–1889
Piperno, A., Arosio, C., Fossati, L., Vigano, M., Trombini, P., Vergani, A., Mancia, G.: Two novel nonsense mutations of HFE gene in five unrelated Italian patients with hemochromatosis. Gastroenterology 2000; 119: 441–445
Powell, L.W.: Hereditary hemochromatosis and iron overload diseases. J. Gastroenterol. Hepatol. 2002; 17(Suppl.): 191–195
Ramrakhiani, S., Bacon, B.R.: Hemochromatosis. Advances in molecular genetics and clinical diagnosis. J. Clin. Gastroenterol. 1998; 27: 41–46
Recklinghausen, v.F.D.: Über Hämochromatose. Berlin. Klin. Wschr. 1889; 26: 925
Rivers, J., Garrahy, P., Robinson, W., Murphy, A.: Reversible cardiac dysfunction in hemochromatosis. Amer. Heart J. 1987; 113: 216–217
Rossi, E., Henderson, S., Chin, C.Y.B., Olynyk, J., Beilby, J.P., Reed, W.D., Jeffrey, G.P.: Genotyping as a diagnostic aid in genetic haemochromatosis. J. Gastroenterol. Hepatol. 1999; 14: 427–430
Sallie, R.W., Reed, W.D., Shilkin, K.B.: Confirmation of the efficacy of hepatic tissue iron index in differentiating genetic hemochromatosis from alcoholic liver disease complicated by alcoholic hemosiderosis. Gut 1991; 32: 207–210
Sanchez, M., Villa, M., Ingelmo, M., Sanz, C., Bruguera, M., Ascas, C., Oliva, R.: Population screening for hemochromatosis: a study in 5370 Spanish blood donors. J. Hepatol. 2003; 38: 745–750
Schumacher, H.R., Straka, P.C., Krikker, M.A., Dudley, A.T.: The arthropathy of hemochromatosis: recent studies. Ann. N.Y. Acad. Sci. 1988; 526: 224–233
Shaheen, N.J., Silverman, L.M., Keku, T., Lawrence, L.B., Rohlfs, E.M., Martin, C.F., Galanko, J., Sandler, R.S.: Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J. Nat. Canc. Inst. 2003; 95: 154–159
Sigurdsson, I., Reyes, J., Kocoshis, S.A., Hansen, T.W.R., Rosh, J., Knisely, A.S.: Neonatal hemochromatosis: outcomes of pharmacologic and surgical therapies. J. Pediatr. Gastroenterol. Nutrit. 1998; 26: 85–89
Stremmel, W., Karner, M., Manzhalii, E., Gittes, W., Hermann, T., Merle, U.: Liver and iron metabolism — A comprehensive hypothesis for the pathogenesis of genetic hemochromatosis (review). Zschr. Gastroenterol. 2007; 45: 71–75
Terada, T., Nakamura, Y.: Iron negative foci in siderotic macroregenerative nodules in human cirrhotic liver. A marker of incipient neoplastic lesion. Arch. Path. Lab. Med. 1989; 113: 916–920
Vadillo, M., Corbella, X., Pac, V., Fernandez-Viladrich, P., Pujol, R.: Multiple liver abscesses due to Yersimia enterocolitica discloses primary hemochromatosis: Three case report and review. Clin. Inf. Dis. 1994; 18: 938–941
Villeneuve, J.-P., Bilodeau, M., Lepage, R., Cote, J., Lefebre, M.: Variability in hepatic iron concentration measurements from needle-biopsy specimens. J. Hepatol. 1996; 25: 172–177
Westra, W.H., Hruban, R.H., Baughman, K.L., Olson, J.L., Porterfield, J.K., Mitchell, M.C., Hutchins, G.M.: Progressive hemochromatotic cardiomyopathy despite reversal of iron deposition after liver transplantation. Amer. J. Clin. Path. 1993; 99: 39–44
Willis, G., Wimperis, J.Z., Lonsdale, R., Fellows, I.W., Watson, M.A., Skipper, L.M., Jennings, B.A.: Incidence of liver disease in people with HFE mutations. Gut 2000; 46: 401–404
Wojcik, J.P., Speechley, M.R., Kertesz, A.E., Chakrabarti, S., Adams, P.C.: Natural history of C 282 Y homozygotes for hemochromatosis. Can. J. Gastroenterol. 2002; 16: 297–302
Yen, A.W., Fancher, T.L., Bowlus, C.L.: Revisiting hereditary hemochromatosis: Current concepts and progress. Amer. J. Med. 2006; 119: 391–399
Acaeruloplasminaemia
Loréal, D., Turein, B., Pigeon, C., Moisan, A., Ropert, M., Morice, P., Gandon, V., Jouanolle, A.-M., Vérin, M., Hider, R.C., Yoshida, K., Brissot, P.: Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J. Hepatol. 2002; 36: 851–856
Mariani, R., Arosio, C., Pelucchi, S., Grisoli, M., Piga, A., Trombini, P., Piperno, A.: Iron chelation therapy in aceruloplasminemia: study of a patient with a novel missense mutation (case report). Gut 2004; 53: 756–758
Yoshida, K., Furihata, K., Takeda, S., Nakamura, A., Yamamoto, K., Morita, H., Hiyamuta, S., Ikeda, S., Shimizu, N., Yanagisawa, N.: A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nature Genet. 1995; 9: 267–272
Atransferrinaemia
Goya, N., Miyazaki, S., Kodate, S., Ushio, B.: A family of congenital atransferrinemia. Blood 1972; 40: 239–245
Heilmeyer, L., Keller, W., Vivell, O., Betke, K., Wöhler, F., Keiderling, W.: Die kongenitale Atransferrinämie. Schweiz. Med. Wschr. 1961; 91: 1203
Rights and permissions
Copyright information
© 2008 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
(2008). Metabolic disorders and storage diseases. In: Hepatology Textbook and Atlas. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-76839-5_31
Download citation
DOI: https://doi.org/10.1007/978-3-540-76839-5_31
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-76838-8
Online ISBN: 978-3-540-76839-5
eBook Packages: MedicineMedicine (R0)